{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:51:10Z","timestamp":1793469070718,"version":"4.5.0"},"reference-count":409,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The number of deaths from colorectal cancer in Japan continues to rise, with over 50,000 deaths recorded in 2018. In the 2024 edition, revisions to all aspects of treatment were undertaken, with corrections and additions made based on knowledge gained since the 2022 version (drug therapy) and the 2019 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer have been prepared to present standard treatment strategies, reduce disparities among institutions, avoid both unnecessary and insufficient treatment, and enhance mutual understanding between healthcare professionals and patients by making these guidelines accessible to the public. These guidelines were developed through consensus by the JSCCR Guideline Committee, following a careful review of evidence retrieved from literature searches and considering the medical insurance system and actual clinical practice in Japan. Therefore, these guidelines serve as a tool for managing colorectal cancer in real-world clinical settings. More specifically, they can be used to support obtaining informed consent from patients and selecting the most appropriate treatment method for each patient. Controversial topics were selected as clinical questions, and recommendations were provided. Each recommendation is accompanied by an evidence classification and a recommendation category, both based on consensus reached by the Guideline Committee members. This article presents the English version of the JSCCR guidelines 2024.<\/jats:p>","DOI":"10.1007\/s10147-025-02899-8","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:04:13Z","timestamp":1762265053000},"page":"2410-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7885-2276","authenticated-orcid":false,"given":"Yusuke","family":"Kinugasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-5860","authenticated-orcid":false,"given":"Kay","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-5709","authenticated-orcid":false,"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-8373","authenticated-orcid":false,"given":"Yutaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Murofushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-3557","authenticated-orcid":false,"given":"Tamotsu","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-0045","authenticated-orcid":false,"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-1199","authenticated-orcid":false,"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-0743","authenticated-orcid":false,"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-3826","authenticated-orcid":false,"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-6887","authenticated-orcid":false,"given":"Hirotoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-9702","authenticated-orcid":false,"given":"Yoshihiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1912-5948","authenticated-orcid":false,"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-8686","authenticated-orcid":false,"given":"Akio","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-5894","authenticated-orcid":false,"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Takiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-6682","authenticated-orcid":false,"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-0968","authenticated-orcid":false,"given":"Kinichi","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1507-1077","authenticated-orcid":false,"given":"Keiji","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-8992","authenticated-orcid":false,"given":"Hiroyasu","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-5323","authenticated-orcid":false,"given":"Shinichi","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Ajioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Society for Cancer of the Colon and Rectum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2899_CR1","volume-title":"JSCCR guidelines 2019 for the treatment of colorectal cancer","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2019","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2019) JSCCR guidelines 2019 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo"},{"key":"2899_CR2","volume-title":"Japanese classification of colorectal, appendiceal, and anal carcinoma, third English edition","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2019","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2019) Japanese classification of colorectal, appendiceal, and anal carcinoma, third English edition. Kanehara & Co., Ltd., Tokyo"},{"key":"2899_CR3","volume-title":"Minds handbook for clinical practice guideline development 2014","author":"T Fukui","year":"2014","unstructured":"Fukui T, Yamaguchi N, Morizane T (2014) Minds handbook for clinical practice guideline development 2014. Igaku Shoin, Tokyo"},{"key":"2899_CR4","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490","journal-title":"BMJ"},{"key":"2899_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"2899_CR6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2008) What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ 336:995\u2013998","journal-title":"BMJ"},{"key":"2899_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"HJ Sch\u00fcnemann","year":"2008","unstructured":"Sch\u00fcnemann HJ, Oxman AD, Brozek J et al (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336:1106\u20131110","journal-title":"BMJ"},{"key":"2899_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2008) Incorporating considerations of resource use into grading recommendations. BMJ 336:1170\u20131173","journal-title":"BMJ"},{"key":"2899_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336:1049\u20131051","journal-title":"BMJ"},{"key":"2899_CR10","doi-asserted-by":"publisher","first-page":"a744","DOI":"10.1136\/bmj.a744","volume":"337","author":"R Jaeschke","year":"2008","unstructured":"Jaeschke R, Guyatt GH, Dellinger P et al (2008) Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337:a744","journal-title":"BMJ"},{"key":"2899_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394","journal-title":"J Clin Epidemiol"},{"key":"2899_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395\u2013400","journal-title":"J Clin Epidemiol"},{"key":"2899_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401\u2013406","journal-title":"J Clin Epidemiol"},{"key":"2899_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G et al (2011) GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias). J Clin Epidemiol 64:407\u2013415","journal-title":"J Clin Epidemiol"},{"key":"2899_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias. J Clin Epidemiol 64:1277\u20131282","journal-title":"J Clin Epidemiol"},{"key":"2899_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 6. Rating the quality of evidence\u2014imprecision. J Clin Epidemiol 64:1283\u20131293","journal-title":"J Clin Epidemiol"},{"key":"2899_CR17","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency. J Clin Epidemiol 64:1294\u20131302","journal-title":"J Clin Epidemiol"},{"key":"2899_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness. J Clin Epidemiol 64:1303\u20131310","journal-title":"J Clin Epidemiol"},{"key":"2899_CR19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S et al (2011) GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64:1311\u20131316","journal-title":"J Clin Epidemiol"},{"key":"2899_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2012.04.012","volume":"66","author":"M Brunetti","year":"2013","unstructured":"Brunetti M, Shemilt I, Pregno S et al (2013) GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 66:140\u2013150","journal-title":"J Clin Epidemiol"},{"key":"2899_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","volume":"66","author":"G Guyatt","year":"2013","unstructured":"Guyatt G, Oxman AD, Sultan S et al (2013) GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66:151\u2013157","journal-title":"J Clin Epidemiol"},{"key":"2899_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Oxman AD, Santesso N et al (2013) GRADE guidelines: 12. Preparing summary of findings tables\u2014binary outcomes. J Clin Epidemiol 66:158\u2013172","journal-title":"J Clin Epidemiol"},{"key":"2899_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719\u2013725","journal-title":"J Clin Epidemiol"},{"key":"2899_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.gie.2011.12.022","volume":"75","author":"KF Binmoeller","year":"2012","unstructured":"Binmoeller KF, Weilert F, Shah J et al (2012) \u201cUnderwater\u201d EMR without submucosal injection for large sessile colorectal polyps (with video). Gastrointest Endosc 75:1086\u20131091","journal-title":"Gastrointest Endosc"},{"key":"2899_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/den.13065","volume":"30","author":"M Iwatate","year":"2018","unstructured":"Iwatate M, Sano Y, Tanaka S et al (2018) Validation study for development of the Japan NBI Expert Team classification of colorectal lesions. Dig Endosc 30:642\u2013651","journal-title":"Dig Endosc"},{"key":"2899_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0016-5107(98)70004-5","volume":"48","author":"Y Saitoh","year":"1998","unstructured":"Saitoh Y, Obara T, Watari J et al (1998) Invasion depth diagnosis of depressed-type early colorectal cancers by combined use of videoendoscopy and chromoendoscopy. Gastrointest Endosc 48:362\u2013370","journal-title":"Gastrointest Endosc"},{"key":"2899_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1148\/radiology.205.1.9314964","volume":"205","author":"J Watari","year":"1997","unstructured":"Watari J, Saitoh Y, Obara T et al (1997) Early nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion. Radiology 205:67\u201374","journal-title":"Radiology"},{"key":"2899_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.gie.2006.06.007","volume":"64","author":"S Tanaka","year":"2006","unstructured":"Tanaka S, Kaltenbach T, Chayama K et al (2006) High magnification colonoscopy (with videos). Gastrointest Endosc 64:604\u2013613","journal-title":"Gastrointest Endosc"},{"key":"2899_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-008-2223-4","volume":"43","author":"S Tanaka","year":"2008","unstructured":"Tanaka S, Oka S, Chayama K (2008) Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol 43:641\u2013651","journal-title":"J Gastroenterol"},{"key":"2899_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1053\/j.gastro.2022.07.002","volume":"163","author":"K Ohata","year":"2022","unstructured":"Ohata K, Kobayashi N, Sakai E et al (2022) Long-term outcomes after endoscopic submucosal dissection for large colorectal epithelial neoplasms: a prospective, multicenter, cohort trial from Japan. Gastroenterology 163:1423-1434.e2","journal-title":"Gastroenterology"},{"key":"2899_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/den.14058","volume":"34","author":"M Sekiguchi","year":"2022","unstructured":"Sekiguchi M, Igarashi A, Mizuguchi Y et al (2022) Cost-effectiveness analysis of endoscopic resection for colorectal laterally spreading tumors: endoscopic submucosal dissection versus piecemeal endoscopic mucosal resection. Dig Endosc 34:553\u2013568","journal-title":"Dig Endosc"},{"key":"2899_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/den.13972","volume":"33","author":"Y Saito","year":"2021","unstructured":"Saito Y, Oka S, Kawamura T et al (2021) Colonoscopy screening and surveillance guidelines. Dig Endosc 33:486\u2013519","journal-title":"Dig Endosc"},{"key":"2899_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1443-1661.2010.01072.x","volume":"23","author":"S Oka","year":"2011","unstructured":"Oka S, Tanaka S, Kanao H et al (2011) Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 23:190\u2013194","journal-title":"Dig Endosc"},{"key":"2899_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00384-014-1885-z","volume":"29","author":"K Kotake","year":"2014","unstructured":"Kotake K, Mizuguchi T, Moritani K et al (2014) Impact of D3 lymph-node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis 29:847\u2013852","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00384-015-2194-x","volume":"30","author":"K Kotake","year":"2015","unstructured":"Kotake K, Kobayashi H, Asano M et al (2015) Influence of extent of lymph-node dissection on survival for patients with pT2 colon cancer. Int J Colorectal Dis 30:813\u2013820","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/bjs.1800691019","volume":"69","author":"RJ Heald","year":"1982","unstructured":"Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 69:613\u2013616","journal-title":"Br J Surg"},{"key":"2899_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0140-6736(93)90207-W","volume":"341","author":"JK MacFarlane","year":"1993","unstructured":"MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457\u2013460","journal-title":"Lancet"},{"key":"2899_CR38","first-page":"335","volume":"181","author":"WE Enker","year":"1995","unstructured":"Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335\u2013346","journal-title":"J Am Coll Surg"},{"key":"2899_CR39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/BF02235475","volume":"44","author":"AC Lowry","year":"2001","unstructured":"Lowry AC, Simmang CL, Boulos P et al (2001) Consensus statement of definitions for anorectal physiology and rectal cancer: report of the Tripartite Consensus Conference on Definitions for Anorectal Physiology and Rectal Cancer, Washington, DC, May 1, 1999. Dis Colon Rectum 44:915\u2013919","journal-title":"Dis Colon Rectum"},{"key":"2899_CR40","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s10350-006-0714-z","volume":"49","author":"K Sugihara","year":"2006","unstructured":"Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663\u20131672","journal-title":"Dis Colon Rectum"},{"key":"2899_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S2468-1253(16)30207-2","volume":"2","author":"S Kitano","year":"2017","unstructured":"Kitano S, Inomata M, Mizusawa J et al (2017) Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2:261\u2013268","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2899_CR42","volume":"33","author":"H Ueno","year":"2023","unstructured":"Ueno H, Hase K, Shiomi A et al (2023) Optimal bowel resection margin in colon cancer surgery: prospective multicentre cohort study with lymph node and feeding artery mapping. Lancet Reg Health West Pac 33:100680","journal-title":"Lancet Reg Health West Pac"},{"key":"2899_CR43","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s10350-004-6290-1","volume":"45","author":"C Ono","year":"2002","unstructured":"Ono C, Yoshinaga K, Enomoto M et al (2002) Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 45:744\u2013749","journal-title":"Dis Colon Rectum"},{"key":"2899_CR44","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1097\/DCR.0b013e318233fc4a","volume":"54","author":"Y Shimada","year":"2011","unstructured":"Shimada Y, Takii Y, Murayama S et al (2011) Intramural and mesorectal distal spread detected by whole-mount sections in the determination of optimal distal resection margin in patients undergoing surgery for rectosigmoid or rectal cancer without preoperative therapy. Dis Colon Rectum 54:1510\u20131520","journal-title":"Dis Colon Rectum"},{"key":"2899_CR45","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/1097-0142(19950801)76:3<388::AID-CNCR2820760307>3.0.CO;2-Y","volume":"76","author":"K Shirouzu","year":"1995","unstructured":"Shirouzu K, Isomoto H, Kakegawa T (1995) Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 76:388\u2013392","journal-title":"Cancer"},{"key":"2899_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3748\/wjg.v11.i3.319","volume":"11","author":"GP Zhao","year":"2005","unstructured":"Zhao GP, Zhou ZG, Lei WZ et al (2005) Pathological study of distal mesorectal cancer spread to determine a proper distal resection margin. World J Gastroenterol 11:319\u2013322","journal-title":"World J Gastroenterol"},{"key":"2899_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10350-005-0296-1","volume":"49","author":"J Pollack","year":"2006","unstructured":"Pollack J, Holm T, Cedermark B et al (2006) Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 49:345\u2013352","journal-title":"Dis Colon Rectum"},{"key":"2899_CR48","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/bjs.5819","volume":"94","author":"MM Lange","year":"2007","unstructured":"Lange MM, den Dulk M, Bossema ER et al (2007) Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 94:1278\u20131284","journal-title":"Br J Surg"},{"key":"2899_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/DCR.0b013e31819f5fa2","volume":"52","author":"K Yamada","year":"2009","unstructured":"Yamada K, Ogata S, Saiki Y et al (2009) Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum 52:1065\u20131071","journal-title":"Dis Colon Rectum"},{"key":"2899_CR50","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1007\/s00464-019-07160-8","volume":"34","author":"M Aubert","year":"2020","unstructured":"Aubert M, Mege D, Panis Y (2020) Total mesorectal excision for low and middle rectal cancer: laparoscopic versus transanal approach\u2014a meta-analysis. Surg Endosc 34:3908\u20133919","journal-title":"Surg Endosc"},{"key":"2899_CR51","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/bjs.11287","volume":"106","author":"SG Larsen","year":"2019","unstructured":"Larsen SG, Pfeffer F, K\u00f8rner H et al (2019) Norwegian moratorium on transanal total mesorectal excision. Br J Surg 106:1120\u20131121","journal-title":"Br J Surg"},{"key":"2899_CR52","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(12)70158-4","volume":"13","author":"S Fujita","year":"2012","unstructured":"Fujita S, Akasu T, Mizusawa J et al (2012) Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph-node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 13:616\u2013621","journal-title":"Lancet Oncol"},{"key":"2899_CR53","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.ejso.2016.07.010","volume":"42","author":"S Saito","year":"2016","unstructured":"Saito S, Fujita S, Mizusawa J et al (2016) Male sexual dysfunction after rectal cancer surgery: results of a randomized trial comparing mesorectal excision with and without lateral lymph-node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol 42:1851\u20131858","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR54","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejso.2018.01.015","volume":"44","author":"M Ito","year":"2018","unstructured":"Ito M, Kobayashi A, Fujita S et al (2018) Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph-node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol 44:463\u2013468","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1072-7515(02)01235-8","volume":"195","author":"E de Santiba\u00f1es","year":"2002","unstructured":"de Santiba\u00f1es E, Lassalle FB, McCormack L et al (2002) Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and long-term outcomes. J Am Coll Surg 195:196\u2013202","journal-title":"J Am Coll Surg"},{"key":"2899_CR56","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00384-017-2806-8","volume":"32","author":"N Nakai","year":"2017","unstructured":"Nakai N, Yamaguchi T, Kinugasa Y et al (2017) Long-term outcomes after resection of para-aortic lymph-node metastasis from left-sided colon and rectal cancer. Int J Colorectal Dis 32:999\u20131007","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR57","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1245\/s10434-009-0692-1","volume":"16","author":"BS Min","year":"2009","unstructured":"Min BS, Kim JS, Kim NK et al (2009) Extended lymph-node dissection for rectal cancer with radiologically diagnosed extramesenteric lymph-node metastasis. Ann Surg Oncol 16:3271\u20133278","journal-title":"Ann Surg Oncol"},{"key":"2899_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jso.21421","volume":"101","author":"PW Choi","year":"2010","unstructured":"Choi PW, Kim HC, Kim AY et al (2010) Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph-node metastasis below the level of renal vessels. J Surg Oncol 101:66\u201371","journal-title":"J Surg Oncol"},{"key":"2899_CR59","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000439547","volume":"32","author":"A Arimoto","year":"2015","unstructured":"Arimoto A, Uehara K, Kato T et al (2015) Clinical significance of para-aortic lymph-node dissection for advanced or metastatic colorectal cancer in the current era of modern chemotherapy. Dig Surg 32:439\u2013444","journal-title":"Dig Surg"},{"key":"2899_CR60","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1245\/s10434-015-5027-9","volume":"23","author":"SU Bae","year":"2016","unstructured":"Bae SU, Han YD, Cho MS et al (2016) Oncologic outcomes of colon cancer patients with extra-regional lymph-node metastasis: comparison of isolated para-aortic lymph-node metastasis with resectable liver metastasis. Ann Surg Oncol 23:1562\u20131568","journal-title":"Ann Surg Oncol"},{"key":"2899_CR61","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1086::AID-CNCR6>3.0.CO;2-6","volume":"83","author":"S Murata","year":"1998","unstructured":"Murata S, Moriya Y, Akasu T et al (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83:1086\u20131093","journal-title":"Cancer"},{"key":"2899_CR62","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0022-5223(99)70106-6","volume":"118","author":"K Kobayashi","year":"1999","unstructured":"Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090\u20131096","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2899_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<274::AID-CNCR5>3.0.CO;2-R","volume":"82","author":"S Ambiru","year":"1998","unstructured":"Ambiru S, Miyazaki M, Ito H et al (1998) Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 82:274\u2013278","journal-title":"Cancer"},{"key":"2899_CR64","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/bjs.9783","volume":"102","author":"A Andres","year":"2015","unstructured":"Andres A, Mentha G, Adam R et al (2015) Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg 102:691\u2013699","journal-title":"Br J Surg"},{"key":"2899_CR65","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jamcollsurg.2005.11.008","volume":"202","author":"SA Shah","year":"2006","unstructured":"Shah SA, Haddad R, Al-Sukhni W et al (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468\u2013475","journal-title":"J Am Coll Surg"},{"key":"2899_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0022-5223(99)70470-8","volume":"117","author":"BJ Robinson","year":"1999","unstructured":"Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66\u201375 (discussion 75\u201376)","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2899_CR68","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s11605-008-0540-9","volume":"12","author":"H Yoshidome","year":"2008","unstructured":"Yoshidome H, Kimura F, Shimizu H et al (2008) Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg 12:1391\u20131398","journal-title":"J Gastrointest Surg"},{"key":"2899_CR69","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1053\/j.seminoncol.2007.01.003","volume":"34","author":"R Adam","year":"2007","unstructured":"Adam R (2007) Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34:S7\u2013S11","journal-title":"Semin Oncol"},{"key":"2899_CR70","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1245\/s10434-011-2061-0","volume":"19","author":"VW Lam","year":"2012","unstructured":"Lam VW, Spiro C, Laurence JM et al (2012) A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19:1292\u20131301","journal-title":"Ann Surg Oncol"},{"key":"2899_CR71","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jso.20926","volume":"97","author":"BS Min","year":"2008","unstructured":"Min BS, Kim NK, Sohn SK et al (2008) Isolated para-aortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 97:136\u2013140","journal-title":"J Surg Oncol"},{"key":"2899_CR72","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.suronc.2016.09.008","volume":"25","author":"JS Wong","year":"2016","unstructured":"Wong JS, Tan GH, Teo MC (2016) Management of para-aortic lymph-node metastasis in colorectal patients: a systematic review. Surg Oncol 25:411\u2013418","journal-title":"Surg Oncol"},{"key":"2899_CR73","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1245\/s10434-016-5732-z","volume":"24","author":"H Nagata","year":"2017","unstructured":"Nagata H, Ishihara S, Hata K et al (2017) Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol 24:1269\u20131280","journal-title":"Ann Surg Oncol"},{"key":"2899_CR74","doi-asserted-by":"publisher","first-page":"20170422","DOI":"10.1259\/bjr.20170422","volume":"90","author":"C Franzese","year":"2017","unstructured":"Franzese C, Fogliata A, Comito T et al (2017) Stereotactic\/hypofractionated body radiation therapy as an effective treatment for lymph-node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol 90:20170422","journal-title":"Br J Radiol"},{"key":"2899_CR75","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/jso.24757","volume":"116","author":"Y Isozaki","year":"2017","unstructured":"Isozaki Y, Yamada S, Kawashiro S et al (2017) Carbon-ion radiotherapy for isolated para-aortic lymph-node recurrence from colorectal cancer. J Surg Oncol 116:932\u2013938","journal-title":"J Surg Oncol"},{"key":"2899_CR76","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3748\/wjg.15.6091","volume":"15","author":"MS Kim","year":"2009","unstructured":"Kim MS, Cho CK, Yang KM et al (2009) Stereotactic body radiotherapy for isolated para-aortic lymph-node recurrence from colorectal cancer. World J Gastroenterol 15:6091\u20136095","journal-title":"World J Gastroenterol"},{"key":"2899_CR77","first-page":"54","volume":"179","author":"J Tschmelitsch","year":"1994","unstructured":"Tschmelitsch J, Kronberger P, Glaser K et al (1994) Survival after surgical treatment of recurrent carcinoma of the rectum. J Am Coll Surg 179:54\u201358","journal-title":"J Am Coll Surg"},{"key":"2899_CR78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","volume":"240","author":"R Adam","year":"2004","unstructured":"Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644\u2013657","journal-title":"Ann Surg"},{"key":"2899_CR79","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11605-006-0070-2","volume":"11","author":"G Nuzzo","year":"2007","unstructured":"Nuzzo G, Giuliante F, Ardito F et al (2007) Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 11:318\u2013324","journal-title":"J Gastrointest Surg"},{"key":"2899_CR80","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1055-3207(18)30126-1","volume":"9","author":"LW Martin","year":"2000","unstructured":"Martin LW, Warren RS (2000) Current management of colorectal liver metastases. Surg Oncol Clin N Am 9:853\u2013876","journal-title":"Surg Oncol Clin N Am"},{"key":"2899_CR81","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0039-6109(02)00051-8","volume":"82","author":"C Penna","year":"2002","unstructured":"Penna C, Nordlinger B (2002) Colorectal metastasis (liver and lung). Surg Clin North Am 82:1075\u20131090","journal-title":"Surg Clin North Am"},{"key":"2899_CR82","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/01.sla.0000128305.90650.71","volume":"239","author":"EK Abdalla","year":"2004","unstructured":"Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection\/ablation for colorectal liver metastases. Ann Surg 239:818\u2013825 (discussion 825\u2013827)","journal-title":"Ann Surg"},{"key":"2899_CR83","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208\u20131215","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"2899_CR84","first-page":"S22","volume":"46","author":"T Kato","year":"2003","unstructured":"Kato T, Yasui K, Hirai T et al (2003) Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46(Suppl):S22\u2013S31","journal-title":"Dis Colon Rectum"},{"key":"2899_CR85","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1148\/radiol.10100729","volume":"257","author":"MC Niekel","year":"2010","unstructured":"Niekel MC, Bipat S, Stoker J (2010) Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and\/or FDG PET\/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257:674\u2013684","journal-title":"Radiology"},{"key":"2899_CR86","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1001\/jama.2014.3740","volume":"311","author":"CA Moulton","year":"2014","unstructured":"Moulton CA, Gu CS, Law CH et al (2014) Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 311:1863\u20131869","journal-title":"JAMA"},{"key":"2899_CR87","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00000658-198403000-00010","volume":"199","author":"JG Fortner","year":"1984","unstructured":"Fortner JG, Silva JS, Golbey RB et al (1984) Multivariate analysis of hepatic metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 199:306\u2013316","journal-title":"Ann Surg"},{"key":"2899_CR88","first-page":"278","volume":"100","author":"KS Hughes","year":"1986","unstructured":"Hughes KS, Simon R, Songhorabodi S et al (1986) Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of pattern of recurrence. Surgery 100:278\u2013284","journal-title":"Surgery"},{"key":"2899_CR89","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/BF01655821","volume":"11","author":"H Ekberg","year":"1987","unstructured":"Ekberg H, Tranberg KG, Andersson R et al (1987) Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11:541\u2013547","journal-title":"World J Surg"},{"key":"2899_CR90","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/hpb.12096","volume":"16","author":"N Battula","year":"2014","unstructured":"Battula N, Tsapralis D, Mayer D et al (2014) Repeat liver resection for recurrent colorectal metastases: a single-center, 13-year experience. HPB (Oxford) 16:157\u2013163","journal-title":"HPB (Oxford)"},{"key":"2899_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-3-642-51873-7_12","volume-title":"Treatment of hepatic metastases of colorectal cancer","author":"B Nordinger","year":"1992","unstructured":"Nordinger B, Jaeck D, Guiguet M et al (1992) Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordinger B, Jaeck D (eds) Treatment of hepatic metastases of colorectal cancer. Springer, Paris, pp 129\u2013146"},{"key":"2899_CR92","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00000658-199804000-00019","volume":"227","author":"B Cady","year":"1998","unstructured":"Cady B, Jenkins RL, Steele GD Jr et al (1998) Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg 227:566\u2013573","journal-title":"Ann Surg"},{"key":"2899_CR93","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00000658-199501000-00009","volume":"221","author":"J Yamamoto","year":"1995","unstructured":"Yamamoto J, Sugihara K, Kosuge T et al (1995) Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg 221:74\u201378","journal-title":"Ann Surg"},{"key":"2899_CR94","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/(SICI)1096-9098(199810)69:2<88::AID-JSO8>3.0.CO;2-X","volume":"69","author":"D Elias","year":"1998","unstructured":"Elias D, Cavalcanti A, Sabourin JC et al (1998) Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 69:88\u201393","journal-title":"J Surg Oncol"},{"key":"2899_CR95","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1200\/JCO.1997.15.3.938","volume":"15","author":"Y Fong","year":"1997","unstructured":"Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938\u2013946","journal-title":"J Clin Oncol"},{"key":"2899_CR96","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/archsurg.137.7.833","volume":"137","author":"N Kokudo","year":"2002","unstructured":"Kokudo N, Miki Y, Sugai S et al (2002) Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 137:833\u2013840","journal-title":"Arch Surg"},{"key":"2899_CR97","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/00365528809096972","volume":"149","author":"H Bismuth","year":"1988","unstructured":"Bismuth H, Castaing D, Traynor O (1988) Surgery for synchronous hepatic metastases of colorectal cancer. Scand J Gastroenterol Suppl 149:144\u2013149","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2899_CR98","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/bjs.1800800302","volume":"80","author":"J Scheele","year":"1993","unstructured":"Scheele J (1993) Hepatectomy for liver metastases. Br J Surg 80:274\u2013276","journal-title":"Br J Surg"},{"key":"2899_CR99","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","volume":"41","author":"R Adam","year":"2015","unstructured":"Adam R, de Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:729\u2013741","journal-title":"Cancer Treat Rev"},{"key":"2899_CR100","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1046\/j.1365-2168.2000.01580.x","volume":"87","author":"MS Rodgers","year":"2000","unstructured":"Rodgers MS, McCall JL (2000) Surgery for colorectal liver metastases with hepatic lymph-node involvement: a systematic review. Br J Surg 87:1142\u20131155","journal-title":"Br J Surg"},{"key":"2899_CR101","first-page":"1081","volume":"84","author":"KT Beckurts","year":"1997","unstructured":"Beckurts KT, H\u00f6lscher AH, Thorban ST et al (1997) Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 84:1081\u20131084","journal-title":"Br J Surg"},{"key":"2899_CR102","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s005340050079","volume":"6","author":"S Nakamura","year":"1999","unstructured":"Nakamura S, Suzuki S, Konno H (1999) Resection of hepatic metastases of colorectal carcinoma: 20 years\u2019 experience. J Hepatobiliary Pancreat Surg 6:16\u201322","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"2899_CR103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0003-4975(98)00269-0","volume":"66","author":"JF Regnard","year":"1998","unstructured":"Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214\u2013218","journal-title":"Ann Thorac Surg"},{"key":"2899_CR104","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1245\/s10434-009-0521-6","volume":"16","author":"DR Carpizo","year":"2009","unstructured":"Carpizo DR, Are C, Jarnagin W et al (2009) Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 16:2138\u20132146","journal-title":"Ann Surg Oncol"},{"key":"2899_CR105","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/JCO.1994.12.7.1491","volume":"12","author":"B Nordlinger","year":"1994","unstructured":"Nordlinger B, Vaillant JC, Guiguet M et al (1994) Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 12:1491\u20131496","journal-title":"J Clin Oncol"},{"key":"2899_CR106","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0002-9610(99)00176-2","volume":"178","author":"J Yamamoto","year":"1999","unstructured":"Yamamoto J, Kosuge T, Shimada K et al (1999) Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 178:275\u2013281","journal-title":"Am J Surg"},{"key":"2899_CR107","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/00000658-200206000-00015","volume":"235","author":"H Petrowsky","year":"2002","unstructured":"Petrowsky H, Gonen M, Jarnagin W et al (2002) Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 235:863\u2013871","journal-title":"Ann Surg"},{"key":"2899_CR108","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0039-6060(01)83158-5","volume":"129","author":"S Suzuki","year":"2001","unstructured":"Suzuki S, Sakaguchi T, Yokoi Y et al (2001) Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 129:421\u2013428","journal-title":"Surgery"},{"key":"2899_CR109","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00268-001-0196-z","volume":"26","author":"S Nagakura","year":"2002","unstructured":"Nagakura S, Shirai Y, Suda T et al (2002) Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 26:141\u2013147","journal-title":"World J Surg"},{"key":"2899_CR110","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00268-004-7214-x","volume":"28","author":"K Tanaka","year":"2004","unstructured":"Tanaka K, Shimada H, Ohta M et al (2004) Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 28:482\u2013487","journal-title":"World J Surg"},{"key":"2899_CR111","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ejso.2006.10.016","volume":"33","author":"A Thelen","year":"2007","unstructured":"Thelen A, Jonas S, Benckert C et al (2007) Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 33:324\u2013328","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jso.20384","volume":"93","author":"P Pessaux","year":"2006","unstructured":"Pessaux P, Lermite E, Brehant O et al (2006) Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 93:1\u20137","journal-title":"J Surg Oncol"},{"key":"2899_CR113","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1245\/s10434-006-9067-z","volume":"13","author":"S Ishiguro","year":"2006","unstructured":"Ishiguro S, Akasu T, Fujimoto Y et al (2006) Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 13:1579\u20131587","journal-title":"Ann Surg Oncol"},{"key":"2899_CR114","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","volume":"14","author":"AC Tree","year":"2013","unstructured":"Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28\u2013e37","journal-title":"Lancet Oncol"},{"key":"2899_CR115","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/1097-0142(19891001)64:7<1418::AID-CNCR2820640709>3.0.CO;2-N","volume":"64","author":"T Goya","year":"1989","unstructured":"Goya T, Miyazawa N, Kondo H et al (1989) Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 64:1418\u20131421","journal-title":"Cancer"},{"key":"2899_CR116","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/archsurg.1992.01420120037006","volume":"127","author":"PM McCormack","year":"1992","unstructured":"McCormack PM, Burt ME, Bains MS et al (1992) Lung resection of colorectal metastases. 10-year results. Arch Surg 127:1403\u20131406","journal-title":"Arch Surg"},{"key":"2899_CR117","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10350-004-6222-0","volume":"45","author":"H Ike","year":"2002","unstructured":"Ike H, Shimada H, Ohki S et al (2002) Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 45:468\u2013473 (discussion 473\u2013475)","journal-title":"Dis Colon Rectum"},{"key":"2899_CR118","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0022-5223(96)70085-5","volume":"112","author":"S Okumura","year":"1996","unstructured":"Okumura S, Kondo H, Tsuboi M et al (1996) Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112:867\u2013874","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2899_CR119","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/0003-4975(92)91435-C","volume":"53","author":"MK McAfee","year":"1992","unstructured":"McAfee MK, Allen MS, Trastek VF et al (1992) Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 53:780\u2013785 (discussion 785\u2013786)","journal-title":"Ann Thorac Surg"},{"key":"2899_CR120","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jjco\/hyl076","volume":"36","author":"R Koga","year":"2006","unstructured":"Koga R, Yamamoto J, Saiura A et al (2006) Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 36:643\u2013648","journal-title":"Jpn J Clin Oncol"},{"key":"2899_CR121","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.athoracsur.2006.02.027","volume":"82","author":"T Iizasa","year":"2006","unstructured":"Iizasa T, Suzuki M, Yoshida S et al (2006) Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 82:254\u2013260","journal-title":"Ann Thorac Surg"},{"key":"2899_CR122","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/SLA.0b013e31826eda3b","volume":"257","author":"T Iida","year":"2013","unstructured":"Iida T, Nomori H, Shiba M et al (2013) Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257:1059\u20131064","journal-title":"Ann Surg"},{"key":"2899_CR123","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.athoracsur.2017.03.021","volume":"104","author":"T Okumura","year":"2017","unstructured":"Okumura T, Boku N, Hishida T et al (2017) Surgical outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann Thorac Surg 104:979\u2013987","journal-title":"Ann Thorac Surg"},{"key":"2899_CR124","doi-asserted-by":"publisher","first-page":"zrad009","DOI":"10.1093\/bjsopen\/zrad009","volume":"7","author":"M van Dorp","year":"2023","unstructured":"van Dorp M, Wolfhagen N, Torensma B et al (2023) Pulmonary metastasectomy and repeat metastasectomy for colorectal pulmonary metastases: outcomes from the Dutch Lung Cancer Audit for Surgery. BJS Open 7:zrad009","journal-title":"BJS Open"},{"key":"2899_CR125","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.athoracsur.2014.05.023","volume":"98","author":"JH Cho","year":"2014","unstructured":"Cho JH, Hamaji M, Allen MS et al (2014) The prognosis of pulmonary metastasectomy depends on the location of the primary colorectal cancer. Ann Thorac Surg 98:1231\u20131237","journal-title":"Ann Thorac Surg"},{"key":"2899_CR126","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1111\/1759-7714.14196","volume":"12","author":"YH Yang","year":"2021","unstructured":"Yang YH, Park SY, Kim HE et al (2021) Effects of mediastinal lymph-node dissection in colorectal cancer-related pulmonary metastasectomy. Thorac Cancer 12:3248\u20133254","journal-title":"Thorac Cancer"},{"key":"2899_CR127","doi-asserted-by":"publisher","first-page":"ivac224","DOI":"10.1093\/icvts\/ivac224","volume":"35","author":"J Ichinose","year":"2022","unstructured":"Ichinose J, Hashimoto K, Matsuura Y et al (2022) Optimal timing for lung metastasectomy in patients with colorectal cancer. Interact Cardiovasc Thorac Surg 35:ivac224","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2899_CR128","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejso.2021.09.020","volume":"48","author":"M van Dorp","year":"2022","unstructured":"van Dorp M, Bousema JE, Torensma B et al (2022) Pulmonary metastasectomy with lymphadenectomy for colorectal pulmonary metastases: a systematic review. Eur J Surg Oncol 48:253\u2013260","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR129","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jamcollsurg.2007.04.039","volume":"205","author":"G Miller","year":"2007","unstructured":"Miller G, Biernacki P, Kemeny NE et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 205:231\u2013238","journal-title":"J Am Coll Surg"},{"key":"2899_CR130","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.surg.2022.10.014","volume":"173","author":"T Horie","year":"2023","unstructured":"Horie T, Kanemitsu Y, Takamizawa Y et al (2023) Prognostic differences between oligometastatic and polymetastatic disease after resection in patients with colorectal cancer and hepatic or lung metastases: retrospective analysis of a large cohort at a single institution. Surgery 173:328\u2013334","journal-title":"Surgery"},{"key":"2899_CR131","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0003-4975(98)00019-8","volume":"65","author":"D Kandioler","year":"1998","unstructured":"Kandioler D, Kr\u00f6mer E, T\u00fcchler H et al (1998) Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 65:909\u2013912","journal-title":"Ann Thorac Surg"},{"key":"2899_CR132","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.amjsurg.2010.08.016","volume":"202","author":"R Kanzaki","year":"2011","unstructured":"Kanzaki R, Higashiyama M, Oda K et al (2011) Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg 202:419\u2013426","journal-title":"Am J Surg"},{"key":"2899_CR133","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/bjs.6682","volume":"96","author":"K Watanabe","year":"2009","unstructured":"Watanabe K, Nagai K, Kobayashi A et al (2009) Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 96:1058\u20131065","journal-title":"Br J Surg"},{"key":"2899_CR134","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00595-012-0373-8","volume":"43","author":"T Hirosawa","year":"2013","unstructured":"Hirosawa T, Itabashi M, Ohnuki T et al (2013) Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study. Surg Today 43:494\u2013499","journal-title":"Surg Today"},{"key":"2899_CR135","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1245\/s10434-012-2726-3","volume":"20","author":"M Gonzalez","year":"2013","unstructured":"Gonzalez M, Poncet A, Combescure C et al (2013) Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 20:572\u2013579","journal-title":"Ann Surg Oncol"},{"key":"2899_CR136","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12957-015-0621-7","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho JH, Kim S, Namgung M et al (2015) The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol 13:222","journal-title":"World J Surg Oncol"},{"key":"2899_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107342","volume":"184","author":"P Ziranu","year":"2023","unstructured":"Ziranu P, Ferrari PA, Guerrera F et al (2023) Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: MetLung Score. Lung Cancer 184:107342","journal-title":"Lung Cancer"},{"key":"2899_CR138","doi-asserted-by":"publisher","first-page":"153303381879493","DOI":"10.1177\/1533033818794936","volume":"17","author":"K Jingu","year":"2018","unstructured":"Jingu K, Matsushita H, Yamamoto T et al (2018) Stereotactic radiotherapy for pulmonary oligometastases from colorectal cancer: a systematic review and meta-analysis. Technol Cancer Res Treat 17:1533033818794936","journal-title":"Technol Cancer Res Treat"},{"key":"2899_CR139","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/cancers15041195","volume":"15","author":"N Garcia-Exposito","year":"2023","unstructured":"Garcia-Exposito N, Ramos R, Navarro-Perez V et al (2023) Stereotactic body radiotherapy versus surgery for lung metastases from colorectal cancer: single-institution results. Cancers (Basel) 15:1195","journal-title":"Cancers (Basel)"},{"key":"2899_CR140","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199002223220802","volume":"322","author":"RA Patchell","year":"1990","unstructured":"Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494\u2013500","journal-title":"N Engl J Med"},{"key":"2899_CR141","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1002\/cncr.25940","volume":"117","author":"PH Go","year":"2011","unstructured":"Go PH, Klaassen Z, Meadows MC et al (2011) Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 117:3630\u20133640","journal-title":"Cancer"},{"key":"2899_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","volume":"6","author":"B Borgelt","year":"1980","unstructured":"Borgelt B, Gelber R, Kramer S et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1\u20139","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2899_CR143","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0360-3016(81)90005-5","volume":"7","author":"JM Kurtz","year":"1981","unstructured":"Kurtz JM, Gelber R, Brady LW et al (1981) The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:891\u2013895","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2899_CR144","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0360-3016(94)90098-1","volume":"28","author":"JC Flickinger","year":"1994","unstructured":"Flickinger JC, Kondziolka D, Lunsford LD et al (1994) A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28:797\u2013802","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2899_CR145","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10151-017-1707-8","volume":"21","author":"IL Silva","year":"2017","unstructured":"Silva IL, Iskandarani M, Hotouras A et al (2017) A systematic review to assess the management of patients with cerebral metastases secondary to colorectal cancer. Tech Coloproctol 21:847\u2013852","journal-title":"Tech Coloproctol"},{"key":"2899_CR146","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/ans.14107","volume":"88","author":"D Mege","year":"2018","unstructured":"Mege D, Sans A, Ouaissi M et al (2018) Brain metastases from colorectal cancer: characteristics and management. ANZ J Surg 88:140\u2013145","journal-title":"ANZ J Surg"},{"key":"2899_CR147","first-page":"768","volume":"9","author":"Y Chang","year":"2022","unstructured":"Chang Y, Wong CE, Lee PH et al (2022) Survival outcome of surgical resection vs. radiotherapy in brain metastasis from colorectal cancer: a meta-analysis. Front Med (Lausanne) 9:768\u2013896","journal-title":"Front Med (Lausanne)"},{"key":"2899_CR148","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gasper","year":"1997","unstructured":"Gasper L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2899_CR149","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575\u2013582","journal-title":"Lancet Oncol"},{"key":"2899_CR150","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419\u2013425","journal-title":"J Clin Oncol"},{"key":"2899_CR151","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"2899_CR152","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","volume":"29","author":"DG Haller","year":"2011","unstructured":"Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465\u20131471","journal-title":"J Clin Oncol"},{"key":"2899_CR153","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP, Wieand HS, O\u2019Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198\u20132204","journal-title":"J Clin Oncol"},{"key":"2899_CR154","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.ejca.2014.05.025","volume":"50","author":"Y Shimada","year":"2014","unstructured":"Shimada Y, Hamaguchi T, Mizusawa J et al (2014) Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2\/D3 lymph-node dissection: final results of JCOG0205. Eur J Cancer 50:2231\u20132240","journal-title":"Eur J Cancer"},{"key":"2899_CR155","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/annonc\/mdu232","volume":"25","author":"M Yoshida","year":"2014","unstructured":"Yoshida M, Ishiguro M, Ikejiri K et al (2014) S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol 25:1743\u20131749","journal-title":"Ann Oncol"},{"key":"2899_CR156","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2468-1253(17)30297-2","volume":"3","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi T, Shimada Y, Mizusawa J et al (2018) Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3:47\u201356","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2899_CR157","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177\u20131188","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"2899_CR158","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.017","volume":"28","author":"T Yoshino","year":"2017","unstructured":"Yoshino T, Yamanaka T, Kotaka M et al (2017) Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration. Ann Oncol 28(Suppl 5):v614","journal-title":"Ann Oncol"},{"key":"2899_CR159","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000354","volume":"3","author":"M Kotaka","year":"2018","unstructured":"Kotaka M, Yamanaka T, Yoshino T et al (2018) Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open 3:e000354","journal-title":"ESMO Open"},{"key":"2899_CR160","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejca.2018.03.009","volume":"96","author":"C Matsuda","year":"2018","unstructured":"Matsuda C, Ishiguro M, Teramukai S et al (2018) A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer 96:54\u201363","journal-title":"Eur J Cancer"},{"key":"2899_CR161","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-022-09267-z","volume":"22","author":"S Sadahiro","year":"2022","unstructured":"Sadahiro S, Sakamoto K, Tsuchiya T et al (2022) Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). BMC Cancer 22:170","journal-title":"BMC Cancer"},{"key":"2899_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162400","volume":"11","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K, Saiura A, Takayama T et al (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400","journal-title":"PLoS ONE"},{"key":"2899_CR163","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1200\/JCO.21.01032","volume":"39","author":"Y Kanemitsu","year":"2021","unstructured":"Kanemitsu Y, Shimizu Y, Mizusawa J et al (2021) Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clin Oncol 39:3789\u20133799","journal-title":"J Clin Oncol"},{"key":"2899_CR164","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/jnci\/djab190","volume":"114","author":"V Formica","year":"2022","unstructured":"Formica V, Sera F, Cremolini C et al (2022) KRAS and BRAF mutations in stage II\/III colon cancer: a systematic review and meta-analysis. J Natl Cancer Inst 114:517\u2013527","journal-title":"J Natl Cancer Inst"},{"key":"2899_CR165","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/0284186X.2014.975839","volume":"54","author":"C B\u00f6ckelman","year":"2015","unstructured":"B\u00f6ckelman C, Engelmann BE, Kaprio T et al (2015) Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 54:5\u201316","journal-title":"Acta Oncol"},{"key":"2899_CR166","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219\u20133226","journal-title":"J Clin Oncol"},{"key":"2899_CR167","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.20.01600","volume":"39","author":"R Cohen","year":"2021","unstructured":"Cohen R, Taieb J, Fiskum J et al (2021) Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol 39:642\u2013651","journal-title":"J Clin Oncol"},{"key":"2899_CR168","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","volume":"321","author":"Simmonds PC; Colorectal Cancer Collaborative Group","year":"2000","unstructured":"Simmonds PC; Colorectal Cancer Collaborative Group (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321:531\u2013535","journal-title":"BMJ"},{"key":"2899_CR169","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278\u20131286","journal-title":"Lancet Oncol"},{"key":"2899_CR170","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539\u20131546","journal-title":"Ann Oncol"},{"key":"2899_CR171","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609\u20131618","journal-title":"N Engl J Med"},{"key":"2899_CR172","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271\u20131282","journal-title":"JAMA"},{"key":"2899_CR173","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"key":"2899_CR174","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized-controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23\u201330","journal-title":"J Clin Oncol"},{"key":"2899_CR175","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"2899_CR176","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"2899_CR177","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012","journal-title":"J Clin Oncol"},{"key":"2899_CR178","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041\u20131047","journal-title":"Lancet"},{"key":"2899_CR179","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx816","volume":"29","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Denda T, Gamoh M et al (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29:624\u2013631","journal-title":"Ann Oncol"},{"key":"2899_CR180","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663\u2013671","journal-title":"J Clin Oncol"},{"key":"2899_CR181","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705","journal-title":"J Clin Oncol"},{"key":"2899_CR182","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"2899_CR183","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","volume":"138","author":"CH K\u00f6hne","year":"2012","unstructured":"K\u00f6hne CH, Hofheinz R, Mineur L et al (2012) First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138:65\u201372","journal-title":"J Cancer Res Clin Oncol"},{"key":"2899_CR184","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D et al (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:497\u2013507","journal-title":"Lancet Oncol"},{"key":"2899_CR185","doi-asserted-by":"publisher","first-page":"JCO2001225","DOI":"10.1200\/JCO.20.01225","volume":"38","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Stein A et al (2020) Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol 38:JCO2001225","journal-title":"J Clin Oncol"},{"key":"2899_CR186","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1200\/JCO.1987.5.10.1559","volume":"5","author":"N Petrelli","year":"1987","unstructured":"Petrelli N, Herrera L, Rustum Y et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559\u20131565","journal-title":"J Clin Oncol"},{"key":"2899_CR187","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","volume":"15","author":"A de Gramont","year":"1997","unstructured":"de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808\u2013815","journal-title":"J Clin Oncol"},{"key":"2899_CR188","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","volume":"23","author":"HI Hurwitz","year":"2005","unstructured":"Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502\u20133508","journal-title":"J Clin Oncol"},{"key":"2899_CR189","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60\u201365","journal-title":"J Clin Oncol"},{"key":"2899_CR190","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282\u20132292","journal-title":"J Clin Oncol"},{"key":"2899_CR191","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097\u20134106","journal-title":"J Clin Oncol"},{"key":"2899_CR192","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","volume":"28","author":"NC Tebbutt","year":"2010","unstructured":"Tebbutt NC, Wilson K, Gebski VJ et al (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol 28:3191\u20133198","journal-title":"J Clin Oncol"},{"key":"2899_CR193","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2004.05.017","volume":"22","author":"K Shirao","year":"2004","unstructured":"Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil\/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT\/LV. J Clin Oncol 22:3466\u20133474","journal-title":"J Clin Oncol"},{"key":"2899_CR194","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","volume":"20","author":"JY Douillard","year":"2002","unstructured":"Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605\u20133616","journal-title":"J Clin Oncol"},{"key":"2899_CR195","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","volume":"20","author":"J Carmichael","year":"2002","unstructured":"Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617\u20133627","journal-title":"J Clin Oncol"},{"key":"2899_CR196","first-page":"236","volume":"15","author":"T Nishina","year":"2016","unstructured":"Nishina T, Moriwaki T, Shimada M et al (2016) Uracil-tegafur and oral leucovorin combined with bevacizumab in elderly patients (aged \u226575 years) with metastatic colorectal cancer: a multicenter, phase ii trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients \\[J-BLUE] study). Clin Colorectal Cancer 15:236\u2013242","journal-title":"Clin Colorectal Cancer"},{"key":"2899_CR197","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ejca.2015.03.007","volume":"51","author":"M Yoshida","year":"2015","unstructured":"Yoshida M, Muro K, Tsuji A et al (2015) Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer 51:935\u2013941","journal-title":"Eur J Cancer"},{"key":"2899_CR198","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1634\/theoncologist.2015-0171","volume":"20","author":"F Pierantonio","year":"2015","unstructured":"Pierantonio F, Cremolini C, Aprile G et al (2015) Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist 20:1261\u20131265","journal-title":"Oncologist"},{"key":"2899_CR199","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ejca.2015.04.013","volume":"51","author":"J Sastre","year":"2015","unstructured":"Sastre J, Massuti B, Pulido G et al (2015) First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the treatment of digestive tumours. Eur J Cancer 51:1371\u20131380","journal-title":"Eur J Cancer"},{"key":"2899_CR200","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ONCO.13523","volume":"26","author":"T Terazawa","year":"2021","unstructured":"Terazawa T, Kato T, Goto M et al (2021) Phase II study of panitumumab monotherapy in chemotherapy-na\u00efve frail or elderly patients with unresectable RAS wild-type colorectal cancer: OGSG 1602. Oncologist 26:17-e47","journal-title":"Oncologist"},{"key":"2899_CR201","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207\u20132218","journal-title":"N Engl J Med"},{"key":"2899_CR202","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW et al (2022) Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomized, open-label, phase 3 study. Lancet Oncol 23:659\u2013670","journal-title":"Lancet Oncol"},{"key":"2899_CR203","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"2899_CR204","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/annonc\/mdv197","volume":"26","author":"S Iwamoto","year":"2015","unstructured":"Iwamoto S, Takahashi T, Tamagawa H et al (2015) FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 26:1427\u20131433","journal-title":"Ann Oncol"},{"key":"2899_CR205","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"RH Xu","year":"2018","unstructured":"Xu RH, Muro K, Morita S et al (2018) Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19:660\u2013671","journal-title":"Lancet Oncol"},{"key":"2899_CR206","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2018) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomized, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"2899_CR207","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"2899_CR208","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdy461","volume":"30","author":"T Yoshino","year":"2019","unstructured":"Yoshino T, Portnoy DC, Obermannova R et al (2019) Biomarker analysis beyond angiogenesis: RAS\/RAF mutation status, tumor sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE\u2014a global phase III study. Ann Oncol 30:124\u2013131","journal-title":"Ann Oncol"},{"key":"2899_CR209","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381:1632\u20131643","journal-title":"N Engl J Med"},{"key":"2899_CR210","first-page":"549","volume":"33","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Arnold D, Taniguchi H et al (2022) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 33:549\u2013570","journal-title":"Ann Oncol"},{"key":"2899_CR211","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2021) NCCN guidelines insights: colon cancer, version 2.2021. J Natl Compr Canc Netw 19:329\u2013339","journal-title":"J Natl Compr Canc Netw"},{"key":"2899_CR212","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.annonc.2022.07.1121","volume":"33","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Argiles G, Oki E et al (2022) Pan-Asian adapted ESMO consensus guidelines for the management of patients with localized colon cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 33:1008\u20131034","journal-title":"Ann Oncol"},{"key":"2899_CR213","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","volume":"23","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1\u201334","journal-title":"Int J Clin Oncol"},{"key":"2899_CR214","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342","journal-title":"Int J Clin Oncol"},{"key":"2899_CR215","unstructured":"National Health Insurance Service (2018) The 2018 National Health Insurance statistical yearbook. Available at: http:\/\/www.nhis.or.kr. Accessed 15 Jan 2023"},{"key":"2899_CR216","volume-title":"National Health and Nutrition survey report","author":"Ministry of Health, Labour and Welfare","year":"2019","unstructured":"Ministry of Health, Labour and Welfare (2019) National Health and Nutrition survey report. Ministry of Health, Labour and Welfare, Tokyo"},{"key":"2899_CR217","unstructured":"GLOBOCAN (2020) Colorectal cancer fact sheet. Available at: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/10_8_9-Colorectum-fact-sheet.pdf. Accessed 10 Feb 2023."},{"key":"2899_CR218","unstructured":"World Health Organization (2018) Global Cancer Observatory. Available at: https:\/\/gco.iarc.fr. Accessed 10 Feb 2023"},{"key":"2899_CR219","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"2899_CR220","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"2899_CR221","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"2899_CR222","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1002\/ijc.32055","volume":"144","author":"M Araghi","year":"2019","unstructured":"Araghi M, Soerjomataram I, Jenkins M et al (2019) Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer 144:2992\u20133000","journal-title":"Int J Cancer"},{"key":"2899_CR223","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum N, Giovannucci E (2019) Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 16:713\u2013732","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2899_CR224","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA et al (2019) Colorectal cancer. Lancet 394:1467\u20131480","journal-title":"Lancet"},{"key":"2899_CR225","first-page":"145","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145\u2013164","journal-title":"CA Cancer J Clin"},{"key":"2899_CR226","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra MS, Laversanne M et al (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66:683\u2013691","journal-title":"Gut"},{"key":"2899_CR227","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115\u2013132","journal-title":"CA Cancer J Clin"},{"key":"2899_CR228","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108","journal-title":"CA Cancer J Clin"},{"key":"2899_CR229","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359\u2013E386","journal-title":"Int J Cancer"},{"key":"2899_CR230","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023\u20131075","journal-title":"Lancet"},{"key":"2899_CR231","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10198-019-01037-2","volume":"20","author":"P Kanavos","year":"2019","unstructured":"Kanavos P, Schurer W, Souliotis K (2019) Cancer medicine prices, availability, affordability and budget impact in Greece. Eur J Health Econ 20:791\u2013801","journal-title":"Eur J Health Econ"},{"key":"2899_CR232","first-page":"2","volume":"19","author":"A Aggarwal","year":"2014","unstructured":"Aggarwal A, Ginsburg O, Fojo T (2014) Cancer economics, policy and politics: what informs the debate? Perspect Oncol Nurs 19:2\u20139","journal-title":"Perspect Oncol Nurs"},{"key":"2899_CR233","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.20.00642","volume":"38","author":"MI Patel","year":"2020","unstructured":"Patel MI, Lopez AM, Blackstock W et al (2020) Cancer disparities and health equity: a policy statement from the American Society of Clinical Oncology. J Clin Oncol 38:3439\u20133448","journal-title":"J Clin Oncol"},{"key":"2899_CR234","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","volume":"12","author":"R Sullivan","year":"2011","unstructured":"Sullivan R, Peppercorn J, Sikora K et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12:933\u2013980","journal-title":"Lancet Oncol"},{"key":"2899_CR235","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","volume":"29","author":"AB Mariotto","year":"2020","unstructured":"Mariotto AB, Enewold L, Zhao J et al (2020) Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomark Prev 29:1304\u20131312","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2899_CR236","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/jama.2015.18603","volume":"315","author":"JE Bekelman","year":"2016","unstructured":"Bekelman JE, Halpern SD, Blankart CR et al (2016) Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA 315:272\u2013283","journal-title":"JAMA"},{"key":"2899_CR237","first-page":"1077","volume":"14","author":"CJ Longo","year":"2006","unstructured":"Longo CJ, Fitch M, Deber RB et al (2006) Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer 14:1077\u20131085","journal-title":"Support Care Cancer"},{"key":"2899_CR238","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","volume":"10","author":"LG Gordon","year":"2017","unstructured":"Gordon LG, Merollini KMD, Lowe A et al (2017) A systematic review of financial toxicity among cancer survivors: we can\u2019t pay the co-pay. Patient 10:295\u2013309","journal-title":"Patient"},{"key":"2899_CR239","first-page":"153","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68:153\u2013165","journal-title":"CA Cancer J Clin"},{"key":"2899_CR240","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12916-015-0433-1","volume":"13","author":"M Kimman","year":"2015","unstructured":"Kimman M, Jan S, Yip CH et al (2015) Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med 13:190","journal-title":"BMC Med"},{"key":"2899_CR241","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","volume":"14","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez R, Leal J, Gray A et al (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14:1165\u20131174","journal-title":"Lancet Oncol"},{"key":"2899_CR242","first-page":"695","volume":"29","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Patel P, McNair H et al (2017) Integrating technology into pathways of cancer care: key opportunities and challenges. Clin Oncol (R Coll Radiol) 29:695\u2013710","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2899_CR243","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019758","volume":"8","author":"C Koshiaris","year":"2018","unstructured":"Koshiaris C, Van den Bruel A, Oke JL et al (2018) Cancer suspicion in general practice, urgent referral, and time to diagnosis: a population-based GP survey nested within a feasibility study using vignettes. BMJ Open 8:e020720","journal-title":"BMJ Open"},{"key":"2899_CR244","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jjco\/hyq169","volume":"41","author":"T Matsuda","year":"2011","unstructured":"Matsuda T, Ajiki W, Marugame T et al (2011) Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 41:139\u2013147","journal-title":"Jpn J Clin Oncol"},{"key":"2899_CR245","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jjco\/hys233","volume":"43","author":"T Matsuda","year":"2013","unstructured":"Matsuda T, Marugame T, Kamo K et al (2013) Cancer incidence and incidence rates in Japan in 2006: based on data from 14 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 43:328\u2013336","journal-title":"Jpn J Clin Oncol"},{"key":"2899_CR246","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12885-015-1276-z","volume":"15","author":"A Kawazoe","year":"2015","unstructured":"Kawazoe A, Shitara K, Fukuoka S et al (2015) A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 15:258","journal-title":"BMC Cancer"},{"key":"2899_CR247","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.4679","volume":"238","author":"SD Richman","year":"2016","unstructured":"Richman SD, Southward K, Chambers P et al (2016) HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 238:562\u2013570","journal-title":"J Pathol"},{"key":"2899_CR248","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/bjc.2014.483","volume":"111","author":"B Ingold Heppner","year":"2014","unstructured":"Ingold Heppner B, Behrens HM, Balschun K et al (2014) HER2\/neu testing in primary colorectal carcinoma. Br J Cancer 111:1977\u20131984","journal-title":"Br J Cancer"},{"key":"2899_CR249","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C et al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738\u2013746","journal-title":"Lancet Oncol"},{"key":"2899_CR250","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino T, Pentheroudakis G, Mishima S et al (2020) JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31:861\u2013872","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"2899_CR251","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/JCO.2021.39.15_suppl.2541","volume":"39","author":"T Yoshino","year":"2021","unstructured":"Yoshino T, Tukachinsky H, Kim JL et al (2021) Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA). J Clin Oncol 39(15_suppl):2541","journal-title":"J Clin Oncol"},{"key":"2899_CR252","doi-asserted-by":"crossref","unstructured":"Pietrantonio F, Di Nicolantonio F, Schrock AB et al (2017) ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst 12:109","DOI":"10.1093\/jnci\/djx089"},{"key":"2899_CR254","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJM199704033361402","volume":"336","author":"B Cedermark","year":"1997","unstructured":"Swedish Rectal Cancer Trial, Cedermark B, Dahlberg M et al (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980\u2013987","journal-title":"N Engl J Med"},{"key":"2899_CR255","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jama.284.8.1008","volume":"284","author":"C Camma","year":"2000","unstructured":"Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284:1008\u20131015","journal-title":"JAMA"},{"key":"2899_CR256","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0140-6736(01)06409-1","volume":"358","author":"Colorectal Cancer Collaborative Group","year":"2001","unstructured":"Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291\u20131304","journal-title":"Lancet"},{"key":"2899_CR257","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638\u2013646","journal-title":"N Engl J Med"},{"key":"2899_CR258","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","volume":"246","author":"KC Peeters","year":"2007","unstructured":"Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693\u2013701","journal-title":"Ann Surg"},{"key":"2899_CR259","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1200\/JCO.2005.05.256","volume":"23","author":"CA Marijnen","year":"2005","unstructured":"Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847\u20131858","journal-title":"J Clin Oncol"},{"key":"2899_CR260","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","volume":"23","author":"KC Peeters","year":"2005","unstructured":"Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol 23:6199\u20136206","journal-title":"J Clin Oncol"},{"key":"2899_CR261","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","volume":"17","author":"Y Francois","year":"1999","unstructured":"Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396","journal-title":"J Clin Oncol"},{"key":"2899_CR262","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114\u20131123","journal-title":"N Engl J Med"},{"key":"2899_CR263","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP G\u00e9rard","year":"2006","unstructured":"G\u00e9rard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3\u20134 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620\u20134625","journal-title":"J Clin Oncol"},{"key":"2899_CR264","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"93","author":"K Bujko","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215\u20131223","journal-title":"Br J Surg"},{"key":"2899_CR265","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","volume":"30","author":"SY Ngan","year":"2012","unstructured":"Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827\u20133833","journal-title":"J Clin Oncol"},{"key":"2899_CR266","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13:579\u2013588","journal-title":"Lancet Oncol"},{"key":"2899_CR267","doi-asserted-by":"publisher","first-page":"djv248","DOI":"10.1093\/jnci\/djv248","volume":"107","author":"CJ Allegra","year":"2015","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ et al (2015) Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst 107:djv248","journal-title":"J Natl Cancer Inst"},{"key":"2899_CR268","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773\u20132780","journal-title":"J Clin Oncol"},{"key":"2899_CR269","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP G\u00e9rard","year":"2010","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol 28:1638\u20131644","journal-title":"J Clin Oncol"},{"key":"2899_CR270","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","volume":"30","author":"JP G\u00e9rard","year":"2012","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558\u20134565","journal-title":"J Clin Oncol"},{"key":"2899_CR271","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","volume":"126","author":"SE Rich","year":"2018","unstructured":"Rich SE, Chow R, Raman S et al (2018) Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 126:547\u2013557","journal-title":"Radiother Oncol"},{"key":"2899_CR272","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1056\/NEJM198611133152014","volume":"315","author":"HO Douglass","year":"1986","unstructured":"Douglass HO, Moertel CG, Mayer RJ et al (1986) Survival after postoperative combination treatment of rectal cancer. N Engl J Med 315:1294\u20131295","journal-title":"N Engl J Med"},{"key":"2899_CR273","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","volume":"25","author":"E Chow","year":"2007","unstructured":"Chow E, Harris K, Fan G et al (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423\u20131436","journal-title":"J Clin Oncol"},{"key":"2899_CR274","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrclinonc.2016.199","volume":"14","author":"EP van der Stok","year":"2017","unstructured":"van der Stok EP, Spaander MCW, Gr\u00fcnhagen DJ et al (2017) Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 14:297\u2013315","journal-title":"Nat Rev Clin Oncol"},{"key":"2899_CR275","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1200\/JCO.2013.50.7442","volume":"31","author":"JA Meyerhardt","year":"2013","unstructured":"Meyerhardt JA, Mangu PB, Flynn PJ et al (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: ASCO clinical practice guideline endorsement. J Clin Oncol 31:4465\u20134470","journal-title":"J Clin Oncol"},{"key":"2899_CR276","unstructured":"National Comprehensive Cancer Network (2023) NCCN clinical practice guidelines in oncology: colon cancer, version 3"},{"key":"2899_CR277","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R et al (2020) Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1291\u20131305","journal-title":"Ann Oncol"},{"key":"2899_CR278","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/DCR.0000000000001984","volume":"64","author":"KM Hardiman","year":"2021","unstructured":"Hardiman KM, Felder SI, Friedman G et al (2021) ASCRS clinical practice guidelines for surveillance and survivorship care after curative treatment of colon and rectal cancer. Dis Colon Rectum 64:517\u2013533","journal-title":"Dis Colon Rectum"},{"key":"2899_CR279","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s00535-004-1339-4","volume":"39","author":"K Kitajima","year":"2004","unstructured":"Kitajima K, Fujimori T, Fujii S et al (2004) Correlations between lymph-node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39:534\u2013543","journal-title":"J Gastroenterol"},{"key":"2899_CR280","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.gastro.2004.04.022","volume":"127","author":"H Ueno","year":"2004","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385\u2013394","journal-title":"Gastroenterology"},{"key":"2899_CR281","first-page":"783","volume":"7","author":"S Tanaka","year":"2000","unstructured":"Tanaka S, Haruma K, Oh-E H et al (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7:783\u2013788","journal-title":"Oncol Rep"},{"key":"2899_CR282","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1440-1746.2011.07041.x","volume":"27","author":"K Nakadoi","year":"2012","unstructured":"Nakadoi K, Tanaka S, Kanao H et al (2012) Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol 27:1057\u20131062","journal-title":"J Gastroenterol Hepatol"},{"key":"2899_CR283","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.gie.2023.01.022","volume":"97","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara Y, Oka S, Tanaka S et al (2023) Nomogram as a novel predictive tool for lymph-node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study. Gastrointest Endosc 97:1119-1128.e5","journal-title":"Gastrointest Endosc"},{"key":"2899_CR284","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(02)09290-5","volume":"359","author":"AM Lacy","year":"2002","unstructured":"Lacy AM, Garc\u00eda-Valdecasas JC, Delgado S et al (2002) Laparoscopy-assisted colectomy versus open colectomy for non-metastatic colon cancer: a randomised trial. Lancet 359:2224\u20132229","journal-title":"Lancet"},{"key":"2899_CR285","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.287.3.321","volume":"287","author":"JC Weeks","year":"2002","unstructured":"Weeks JC, Nelson H, Gelber S et al (2002) Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 287:321\u2013328","journal-title":"JAMA"},{"key":"2899_CR286","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1056\/NEJMoa032651","volume":"350","author":"H Nelson","year":"2004","unstructured":"Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent DJ et al (2004) A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 350:2050\u20132059","journal-title":"N Engl J Med"},{"key":"2899_CR287","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1470-2045(05)70221-7","volume":"6","author":"R Veldkamp","year":"2005","unstructured":"Veldkamp R, Kuhry E, Hop WC et al (2005) Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 6:477\u2013484","journal-title":"Lancet Oncol"},{"key":"2899_CR288","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(04)15947-3","volume":"363","author":"KL Leung","year":"2004","unstructured":"Leung KL, Kwok SP, Lam SC et al (2004) Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 363:1187\u20131192","journal-title":"Lancet"},{"key":"2899_CR289","first-page":"CD003145","volume":"2005","author":"W Schwenk","year":"2005","unstructured":"Schwenk W, Haase O, Neudecker J et al (2005) Short-term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005:CD003145","journal-title":"Cochrane Database Syst Rev"},{"key":"2899_CR290","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(05)66545-2","volume":"365","author":"PJ Guillou","year":"2005","unstructured":"Guillou PJ, Quirke P, Thorpe H et al (2005) Short-term endpoints of conventional versus laparoscopic-assisted surgery in colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365:1718\u20131726","journal-title":"Lancet"},{"key":"2899_CR291","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/SLA.0000000000000499","volume":"260","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto S, Inomata M, Katayama H et al (2014) Short-term surgical outcomes from a randomized-controlled trial to evaluate laparoscopic and open D3 dissection for stage II\/III colon cancer: JCOG 0404. Ann Surg 260:23\u201330","journal-title":"Ann Surg"},{"key":"2899_CR292","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2006.09.7758","volume":"25","author":"DG Jayne","year":"2007","unstructured":"Jayne DG, Guillou PJ, Thorpe H et al (2007) Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial. J Clin Oncol 25:3061\u20133068","journal-title":"J Clin Oncol"},{"key":"2899_CR293","first-page":"CD003432","volume":"2008","author":"E Kuhry","year":"2008","unstructured":"Kuhry E, Schwenk WF, Gaupset R et al (2008) Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008:CD003432","journal-title":"Cochrane Database Syst Rev"},{"key":"2899_CR294","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(08)70310-3","volume":"10","author":"M Buunen","year":"2009","unstructured":"Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R et al (2009) Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 10:44\u201352","journal-title":"Lancet Oncol"},{"key":"2899_CR295","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/bjs.8945","volume":"100","author":"BL Green","year":"2013","unstructured":"Green BL, Marshall HC, Collinson F et al (2013) Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg 100:75\u201382","journal-title":"Br J Surg"},{"key":"2899_CR296","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s11605-014-2697-8","volume":"19","author":"B Xiong","year":"2015","unstructured":"Xiong B, Ma L, Huang W et al (2015) Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis of eight studies. J Gastrointest Surg 19:516\u2013526","journal-title":"J Gastrointest Surg"},{"key":"2899_CR297","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/codi.12872","volume":"17","author":"M Broholm","year":"2015","unstructured":"Broholm M, Pommergaard HC, G\u00f6gen\u00fcr I (2015) Possible benefits of robot-assisted rectal cancer surgery regarding urological and sexual dysfunction: a systematic review and meta-analysis. Colorectal Dis 17:375\u2013381","journal-title":"Colorectal Dis"},{"key":"2899_CR298","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1007\/s00464-016-4892-z","volume":"30","author":"X Zhang","year":"2016","unstructured":"Zhang X, Wei Z, Bie M et al (2016) Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis. Surg Endosc 30:5601\u20135614","journal-title":"Surg Endosc"},{"key":"2899_CR299","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12957-016-0816-6","volume":"14","author":"Y Sun","year":"2016","unstructured":"Sun Y, Xu H, Li Z et al (2016) Robotic versus laparoscopic low anterior resection for rectal cancer: a meta-analysis. World J Surg Oncol 14:61","journal-title":"World J Surg Oncol"},{"key":"2899_CR300","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/SLA.0000000000002523","volume":"267","author":"FP Prete","year":"2018","unstructured":"Prete FP, Pezzolla A, Prete F et al (2018) Robotic versus laparoscopic minimally invasive surgery for rectal cancer: a systematic review and meta-analysis of randomized-controlled trials. Ann Surg 267:1034\u20131046","journal-title":"Ann Surg"},{"key":"2899_CR301","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00268-018-04896-7","volume":"43","author":"KT Ng","year":"2019","unstructured":"Ng KT, Tsia AKV, Chong VYL (2019) Robotic versus conventional laparoscopic surgery for colorectal cancer: a systematic review and meta-analysis with trial sequential analysis. World J Surg 43:1146\u20131161","journal-title":"World J Surg"},{"key":"2899_CR302","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.asjsur.2019.11.003","volume":"43","author":"C Han","year":"2020","unstructured":"Han C, Yan P, Jing W et al (2020) Clinical, pathological, and oncologic outcomes of robotic-assisted versus laparoscopic proctectomy for rectal cancer: a meta-analysis of randomized controlled studies. Asian J Surg 43:880\u2013890","journal-title":"Asian J Surg"},{"key":"2899_CR303","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rcs.2164","volume":"17","author":"IJY Wee","year":"2021","unstructured":"Wee IJY, Kuo LJ, Ngu JC (2021) Urological and sexual function after robotic and laparoscopic surgery for rectal cancer: a systematic review, meta-analysis and meta-regression. Int J Med Robot 17:1\u20138","journal-title":"Int J Med Robot"},{"key":"2899_CR304","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/bjs\/znaa067","volume":"108","author":"CA Fleming","year":"2021","unstructured":"Fleming CA, Cullinane C, Lynch N et al (2021) Urogenital function following robotic and laparoscopic rectal cancer surgery: meta-analysis. Br J Surg 108:128\u2013137","journal-title":"Br J Surg"},{"key":"2899_CR305","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/DCR.0000000000002535","volume":"65","author":"J Flynn","year":"2022","unstructured":"Flynn J, Larach JT, Kong JCH et al (2022) Patient-related functional outcomes after robotic-assisted rectal surgery compared with a laparoscopic approach: a systematic review and meta-analysis. Dis Colon Rectum 65:1191\u20131204","journal-title":"Dis Colon Rectum"},{"key":"2899_CR306","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12893-022-01592-1","volume":"22","author":"B Tang","year":"2022","unstructured":"Tang B, Gao G, Ye S et al (2022) Male urogenital function after robot-assisted and laparoscopic total mesorectal excision for rectal cancer: a prospective cohort study. BMC Surg 22:185","journal-title":"BMC Surg"},{"key":"2899_CR307","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4103\/jcrt.JCRT_533_18","volume":"16","author":"X Wang","year":"2020","unstructured":"Wang X, Cao G, Mao W et al (2020) Robot-assisted versus laparoscopic surgery for rectal cancer: a systematic review and meta-analysis. J Cancer Res Ther 16:979\u2013989","journal-title":"J Cancer Res Ther"},{"key":"2899_CR308","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jama.2017.7219","volume":"318","author":"D Jayne","year":"2017","unstructured":"Jayne D, Pigazzi A, Marshall H et al (2017) Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 318:1569\u20131580","journal-title":"JAMA"},{"key":"2899_CR309","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00384-011-1313-6","volume":"27","author":"FJ Collinson","year":"2012","unstructured":"Collinson FJ, Jayne DG, Pigazzi A et al (2012) An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. Int J Colorectal Dis 27:233\u2013241","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR310","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/SLA.0000000000000613","volume":"261","author":"EJ Park","year":"2015","unstructured":"Park EJ, Cho MS, Baek SJ et al (2015) Long-term oncologic outcomes of robotic low anterior resection for rectal cancer: a comparative study with laparoscopic surgery. Ann Surg 261:129\u2013137","journal-title":"Ann Surg"},{"key":"2899_CR311","doi-asserted-by":"publisher","first-page":"zrab083","DOI":"10.1093\/bjsopen\/zrab083","volume":"5","author":"T Matsuyama","year":"2021","unstructured":"Matsuyama T, Endo H, Yamamoto H et al (2021) Outcomes of robot-assisted versus conventional laparoscopic low anterior resection in patients with rectal cancer: propensity-matched analysis of the National Clinical Database in Japan. BJS Open 5:zrab083","journal-title":"BJS Open"},{"key":"2899_CR312","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S2468-1253(22)00248-5","volume":"7","author":"Q Feng","year":"2022","unstructured":"Feng Q, Yuan W, Li T et al (2022) Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 7:991\u20131004","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2899_CR313","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s11605-017-3460-8","volume":"21","author":"M Schootman","year":"2017","unstructured":"Schootman M, Hendren S, Loux T et al (2017) Differences in effectiveness and use of robotic surgery in patients undergoing minimally invasive colectomy. J Gastrointest Surg 21:1296\u20131303","journal-title":"J Gastrointest Surg"},{"key":"2899_CR314","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.asjsur.2018.11.007","volume":"42","author":"YJ Huang","year":"2019","unstructured":"Huang YJ, Kang YN, Huang YM et al (2019) Effects of laparoscopic vs robotic-assisted mesorectal excision for rectal cancer: an updated systematic review and meta-analysis of randomized-controlled trials. Asian J Surg 42:657\u2013666","journal-title":"Asian J Surg"},{"key":"2899_CR315","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.asjsur.2018.11.002","volume":"42","author":"S Ma","year":"2019","unstructured":"Ma S, Chen Y, Chen Y et al (2019) Short-term outcomes of robotic-assisted right colectomy compared with laparoscopic surgery: a systematic review and meta-analysis. Asian J Surg 42:589\u2013598","journal-title":"Asian J Surg"},{"key":"2899_CR316","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00384-021-03966-y","volume":"36","author":"N Dohrn","year":"2021","unstructured":"Dohrn N, Klein MF, G\u00f6genur I (2021) Robotic versus laparoscopic right colectomy for colon cancer: a nationwide cohort study. Int J Colorectal Dis 36:2147\u20132158","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR317","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11701-021-01319-z","volume":"16","author":"EM Clarke","year":"2022","unstructured":"Clarke EM, Rahme J, Larach T et al (2022) Robotic versus laparoscopic right hemicolectomy: a retrospective cohort study of the Binational Colorectal Cancer Database. J Robot Surg 16:927\u2013933","journal-title":"J Robot Surg"},{"key":"2899_CR318","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00464-021-08782-7","volume":"36","author":"P Cuk","year":"2022","unstructured":"Cuk P, Kj\u00e6r MD, Mogensen CB et al (2022) Short-term outcomes in robot-assisted compared to laparoscopic colon cancer resections: a systematic review and meta-analysis. Surg Endosc 36:32\u201346","journal-title":"Surg Endosc"},{"key":"2899_CR319","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3390\/jcm11092387","volume":"11","author":"P Tschann","year":"2022","unstructured":"Tschann P, Szeverinski P, Weigl MP et al (2022) Short- and long-term outcome of laparoscopic- versus robotic-assisted right colectomy: a systematic review and meta-analysis. J Clin Med 11:2387","journal-title":"J Clin Med"},{"key":"2899_CR320","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1245\/s10434-018-6752-7","volume":"25","author":"G Spinoglio","year":"2018","unstructured":"Spinoglio G, Bianchi PP, Marano A et al (2018) Robotic versus laparoscopic right colectomy with complete mesocolic excision for the treatment of colon cancer: perioperative outcomes and 5-year survival in a consecutive series of 202 patients. Ann Surg Oncol 25:3580\u20133586","journal-title":"Ann Surg Oncol"},{"key":"2899_CR321","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00464-018-6563-8","volume":"33","author":"JS Park","year":"2019","unstructured":"Park JS, Kang H, Park SY et al (2019) Long-term oncologic outcomes after robotic versus laparoscopic right colectomy: a prospective randomized study. Surg Endosc 33:2975\u20132981","journal-title":"Surg Endosc"},{"key":"2899_CR322","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1007\/s00464-017-5999-6","volume":"32","author":"KA Mirkin","year":"2018","unstructured":"Mirkin KA, Kulaylat AS, Hollenbeak CS et al (2018) Robotic versus laparoscopic colectomy for stage I-III colon cancer: oncologic and long-term survival outcomes. Surg Endosc 32:2894\u20132901","journal-title":"Surg Endosc"},{"key":"2899_CR323","doi-asserted-by":"crossref","unstructured":"(1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Lancet 345:939\u2013944","DOI":"10.1016\/S0140-6736(95)90696-7"},{"key":"2899_CR324","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109\u20133116","journal-title":"J Clin Oncol"},{"key":"2899_CR325","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O\u2019Connell MJ, Allegra CJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768\u20133774","journal-title":"J Clin Oncol"},{"key":"2899_CR326","first-page":"22","volume":"19","author":"E Sunami","year":"2020","unstructured":"Sunami E, Kusumoto T, Ota M et al (2020) S-1 and oxaliplatin versus tegafur-uracil and leucovorin as postoperative adjuvant chemotherapy in patients with high-risk stage III colon cancer (ACTS-CC 02): a randomized, open-label, multicenter, phase III superiority trial. Clin Colorectal Cancer 19:22\u201331","journal-title":"Clin Colorectal Cancer"},{"key":"2899_CR327","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2019.2572","volume":"5","author":"T Yoshino","year":"2019","unstructured":"Yoshino T, Yamanaka T, Oki E et al (2019) Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE Phase 3 randomized clinical trial. JAMA Oncol 5:1574\u20131581","journal-title":"JAMA Oncol"},{"key":"2899_CR328","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Meyerhardt J, Iveson T et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomized, phase 3 trials. Lancet Oncol 21:1620\u20131629","journal-title":"Lancet Oncol"},{"key":"2899_CR329","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/jnci\/djab190","volume":"114","author":"V Formica","year":"2022","unstructured":"Formica V, Sera F, Cremolini C et al (2022) KRAS and BRAF mutations in stage II and III colon cancer: a systematic review and meta-analysis. J Natl Cancer Inst 114:517\u2013527","journal-title":"J Natl Cancer Inst"},{"key":"2899_CR330","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andr\u00e9","year":"2015","unstructured":"Andr\u00e9 T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33:4176\u20134187","journal-title":"J Clin Oncol"},{"key":"2899_CR331","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.ejca.2009.04.018","volume":"45","author":"G Des Guetz","year":"2009","unstructured":"Des Guetz G, Schischmanoff O, Nicolas P et al (2009) Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 45:1890\u20131896","journal-title":"Eur J Cancer"},{"key":"2899_CR332","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1016\/j.ejca.2010.05.009","volume":"46","author":"C Guastadisegni","year":"2010","unstructured":"Guastadisegni C, Colafranceschi M, Ottini L et al (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 46:2788\u20132798","journal-title":"Eur J Cancer"},{"key":"2899_CR333","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247\u2013257","journal-title":"N Engl J Med"},{"key":"2899_CR334","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","volume":"29","author":"G Hutchins","year":"2011","unstructured":"Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261\u20131270","journal-title":"J Clin Oncol"},{"key":"2899_CR335","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.20.01600","volume":"39","author":"R Cohen","year":"2021","unstructured":"Cohen R, Taieb J, Fiskum J et al (2021) Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol 39:642\u2013651","journal-title":"J Clin Oncol"},{"key":"2899_CR336","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.suronc.2020.03.009","volume":"34","author":"E O\u2019Connell","year":"2020","unstructured":"O\u2019Connell E, Reynolds IS, McNamara DA et al (2020) Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Surg Oncol 34:57\u201362","journal-title":"Surg Oncol"},{"key":"2899_CR337","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/his.14710","volume":"81","author":"M Swets","year":"2022","unstructured":"Swets M, Graham Martinez C et al (2022) Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature. Histopathology 81:352\u2013362","journal-title":"Histopathology"},{"key":"2899_CR338","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J et al (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386:2363\u20132376","journal-title":"N Engl J Med"},{"key":"2899_CR339","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/DCR.0b013e3181a1d994","volume":"52","author":"H Kobayashi","year":"2009","unstructured":"Kobayashi H, Mochizuki H, Kato T et al (2009) Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection. Dis Colon Rectum 52:567\u2013576","journal-title":"Dis Colon Rectum"},{"key":"2899_CR340","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/bjs.4975","volume":"92","author":"M Ueno","year":"2005","unstructured":"Ueno M, Oya M, Azekura K et al (2005) Incidence and prognostic significance of lateral lymph-node metastasis in patients with advanced low rectal cancer. Br J Surg 92:756\u2013763","journal-title":"Br J Surg"},{"key":"2899_CR341","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.surg.2017.02.005","volume":"162","author":"Y Kanemitsu","year":"2017","unstructured":"Kanemitsu Y, Komori K, Shida D et al (2017) Potential impact of lateral lymph-node dissection (LLND) for low rectal cancer on prognoses and local control: a comparison of 2 high-volume centers in Japan. Surgery 162:303\u2013314","journal-title":"Surgery"},{"key":"2899_CR342","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00384-021-03858-1","volume":"36","author":"H Inoue","year":"2021","unstructured":"Inoue H, Sakai K, Nozawa H et al (2021) Therapeutic significance of D3 dissection for low rectal cancer: comparison of dissection between lateral pelvic lymph nodes and lymph nodes along the root of the inferior mesenteric artery. Int J Colorectal Dis 36:1263\u20131270","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR343","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00000658-200108000-00008","volume":"234","author":"H Ueno","year":"2001","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2001) Prognostic determinant of patients with lateral nodal involvement by rectal cancer. Ann Surg 234:190\u2013197","journal-title":"Ann Surg"},{"key":"2899_CR344","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/SLA.0b013e3182565d9d","volume":"255","author":"T Akiyoshi","year":"2012","unstructured":"Akiyoshi T, Watanabe T, Miyata S et al (2012) Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph-node metastasis in low rectal cancer. Ann Surg 255:1129\u20131134","journal-title":"Ann Surg"},{"key":"2899_CR345","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s00268-016-3444-y","volume":"40","author":"H Ozawa","year":"2016","unstructured":"Ozawa H, Kotake K, Hosaka M et al (2016) Impact of lateral pelvic lymph-node dissection on the survival of patients with T3 and T4 low rectal cancer. World J Surg 40:1492\u20131499","journal-title":"World J Surg"},{"key":"2899_CR346","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1245\/s10434-021-10312-7","volume":"28","author":"K Hida","year":"2021","unstructured":"Hida K, Nishizaki D, Sumii A et al (2021) Prognostic impact of lateral pelvic node dissection on survival of patients in low rectal cancer subgroup based on lymph node size. Ann Surg Oncol 28:6179\u20136188","journal-title":"Ann Surg Oncol"},{"key":"2899_CR347","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/01.sla.0000225359.72553.8c","volume":"245","author":"H Ueno","year":"2007","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2007) Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg 245:80\u201387","journal-title":"Ann Surg"},{"key":"2899_CR348","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1002\/cam4.2643","volume":"9","author":"X Yang","year":"2020","unstructured":"Yang X, Yang S, Hu T et al (2020) What is the role of lateral lymph-node dissection in rectal cancer patients with clinically suspected lateral lymph-node metastasis after preoperative chemoradiotherapy? A meta-analysis and systematic review. Cancer Med 9:4477\u20134489","journal-title":"Cancer Med"},{"key":"2899_CR349","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1200\/JCO.18.00032","volume":"37","author":"A Ogura","year":"2019","unstructured":"Ogura A, Konishi T, Cunningham C et al (2019) Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes. J Clin Oncol 37:33\u201343","journal-title":"J Clin Oncol"},{"key":"2899_CR350","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1245\/s10434-020-08481-y","volume":"27","author":"MJ Kim","year":"2020","unstructured":"Kim MJ, Chang GJ, Lim HK et al (2020) Oncological impact of lateral lymph-node dissection after preoperative chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol 27:3525\u20133533","journal-title":"Ann Surg Oncol"},{"key":"2899_CR351","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/SLA.0000000000002212","volume":"266","author":"S Fujita","year":"2017","unstructured":"Fujita S, Mizusawa J, Kanemitsu Y et al (2017) Mesorectal excision with or without lateral lymph-node dissection for clinical stage II\/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg 266:201\u2013207","journal-title":"Ann Surg"},{"key":"2899_CR352","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/bjs.11513","volume":"107","author":"S Tsukamoto","year":"2020","unstructured":"Tsukamoto S, Fujita S, Ota M et al (2020) Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph-node dissection in rectal cancer (JCOG0212). Br J Surg 107:586\u2013594","journal-title":"Br J Surg"},{"key":"2899_CR353","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(12)70158-4","volume":"13","author":"S Fujita","year":"2012","unstructured":"Fujita S, Akasu T, Mizusawa J et al (2012) Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph-node dissection for clinical stage II or III lower rectal cancer (JCOG0212). Lancet Oncol 13:616\u2013621","journal-title":"Lancet Oncol"},{"key":"2899_CR354","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejso.2018.01.015","volume":"44","author":"M Ito","year":"2018","unstructured":"Ito M, Kobayashi A, Fujita S et al (2018) Urinary dysfunction after rectal cancer surgery: results from a randomized trial comparing mesorectal excision with and without lateral lymph-node dissection (JCOG0212). Eur J Surg Oncol 44:463\u2013468","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR355","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.ejso.2016.07.010","volume":"42","author":"S Saito","year":"2016","unstructured":"Saito S, Fujita S, Mizusawa J et al (2016) Male sexual dysfunction after rectal cancer surgery: results of a randomized trial comparing mesorectal excision with and without lateral lymph-node dissection (JCOG0212). Eur J Surg Oncol 42:1851\u20131858","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR356","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/DCR.0000000000001762","volume":"63","author":"YN You","year":"2020","unstructured":"You YN, Hardiman KM, Bafford A et al (2020) The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum 63:1191\u20131222","journal-title":"Dis Colon Rectum"},{"key":"2899_CR357","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1007\/BF02234784","volume":"44","author":"H Nagawa","year":"2001","unstructured":"Nagawa H, Muto T, Sunouchi K et al (2001) Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum 44:1274\u20131280","journal-title":"Dis Colon Rectum"},{"key":"2899_CR358","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1245\/s10434-015-5021-2","volume":"23","author":"S Ogawa","year":"2016","unstructured":"Ogawa S, Hida J, Ike H et al (2016) Selection of lymph node-positive cases based on perirectal and lateral pelvic lymph nodes using magnetic resonance imaging: study of the Japanese Society for Cancer of the Colon and Rectum. Ann Surg Oncol 23:1187\u20131194","journal-title":"Ann Surg Oncol"},{"key":"2899_CR359","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/ans.18029","volume":"93","author":"K Kawai","year":"2023","unstructured":"Kawai K, Shiomi A, Miura T et al (2023) Optimal diagnostic criteria for lateral lymph-node dissection using magnetic resonance imaging: a multicenter prospective study. ANZ J Surg 93:206\u2013213","journal-title":"ANZ J Surg"},{"key":"2899_CR360","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1001\/jama.1990.03450110090034","volume":"264","author":"NIH Consensus Conference","year":"1990","unstructured":"NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444\u20131450","journal-title":"JAMA"},{"key":"2899_CR361","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731\u20131740","journal-title":"N Engl J Med"},{"key":"2899_CR362","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol 34:10\u201332","journal-title":"Ann Oncol"},{"key":"2899_CR363","unstructured":"NCCN clinical practice guidelines in oncology: rectal cancer, Version 1.2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf. Accessed 14 May 2024"},{"key":"2899_CR364","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","volume":"23","author":"KC Peeters","year":"2005","unstructured":"Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients. J Clin Oncol 23:6199\u20136206","journal-title":"J Clin Oncol"},{"key":"2899_CR365","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.ejca.2014.06.020","volume":"50","author":"LM Wiltink","year":"2014","unstructured":"Wiltink LM, Chen TY, Nout RA et al (2014) Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Eur J Cancer 50:2390\u20132398","journal-title":"Eur J Cancer"},{"key":"2899_CR366","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1200\/JCO.2005.02.543","volume":"23","author":"H Birgisson","year":"2005","unstructured":"Birgisson H, P\u00e5hlman L, Gunnarsson U et al (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126\u20136131","journal-title":"J Clin Oncol"},{"key":"2899_CR367","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR et al (2023) Preoperative treatment of locally advanced rectal cancer. N Engl J Med 389:322\u2013334","journal-title":"N Engl J Med"},{"key":"2899_CR368","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.2009.25.8541","volume":"28","author":"C Fern\u00e1ndez-Martos","year":"2010","unstructured":"Fern\u00e1ndez-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant CAPOX compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in MRI-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28:859\u2013865","journal-title":"J Clin Oncol"},{"key":"2899_CR369","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","volume":"26","author":"C Fernandez-Martos","year":"2015","unstructured":"Fernandez-Martos C, Garcia-Albeniz X, Pericay C et al (2015) Chemoradiation, surgery, and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26:1722\u20131728","journal-title":"Ann Oncol"},{"key":"2899_CR370","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702\u2013715","journal-title":"Lancet Oncol"},{"key":"2899_CR371","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29\u201342","journal-title":"Lancet Oncol"},{"key":"2899_CR372","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2023.02.027","volume":"85","author":"RR Bahadoer","year":"2023","unstructured":"Bahadoer RR, Hospers GAP, Marijnen CAM et al (2023) Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. Eur J Cancer 85:139\u2013149","journal-title":"Eur J Cancer"},{"key":"2899_CR373","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery: a five-year follow-up of the RAPIDO trial. Ann Surg 278:e766\u2013e772","journal-title":"Ann Surg"},{"key":"2899_CR374","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30097","volume":"3","author":"A Kasi","year":"2020","unstructured":"Kasi A, Abbasi S, Handa S et al (2020) Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open 3:e2030097","journal-title":"JAMA Netw Open"},{"key":"2899_CR375","doi-asserted-by":"publisher","first-page":"e1555","DOI":"10.1002\/onco.13824","volume":"26","author":"S Liu","year":"2021","unstructured":"Liu S, Jiang T, Xiao L et al (2021) Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist 26:e1555\u2013e1566","journal-title":"Oncologist"},{"key":"2899_CR376","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.1245\/s10434-021-09837-8","volume":"28","author":"JC Kong","year":"2021","unstructured":"Kong JC, Soucisse M, Michael M et al (2021) Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and meta-analysis of oncological and operative outcomes. Ann Surg Oncol 28:7476\u20137486","journal-title":"Ann Surg Oncol"},{"key":"2899_CR377","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1245\/s10434-019-07342-7","volume":"26","author":"T Konishi","year":"2019","unstructured":"Konishi T, Shinozaki E, Murofushi K et al (2019) Phase II trial of neoadjuvant chemotherapy, chemoradiotherapy, and laparoscopic surgery with selective lateral node dissection for poor-risk low rectal cancer. Ann Surg Oncol 26:2507\u20132513","journal-title":"Ann Surg Oncol"},{"key":"2899_CR378","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ et al (2022) Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 40:2546\u20132556","journal-title":"J Clin Oncol"},{"key":"2899_CR379","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00384-017-2939-9","volume":"33","author":"FJ van der Sluis","year":"2018","unstructured":"van der Sluis FJ, van Westreenen HL, van Etten B et al (2018) Pretreatment identification of patients likely to have pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis 33:149\u2013157","journal-title":"Int J Colorectal Dis"},{"key":"2899_CR380","doi-asserted-by":"publisher","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","volume":"4","author":"A Cercek","year":"2018","unstructured":"Cercek A, Roxburgh CSD, Strombom P et al (2018) Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 4:e180071","journal-title":"JAMA Oncol"},{"key":"2899_CR381","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before TME versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29\u201342","journal-title":"Lancet Oncol"},{"key":"2899_CR382","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","volume":"30","author":"IJ Park","year":"2012","unstructured":"Park IJ, You YN, Agarwal A et al (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770\u20131776","journal-title":"J Clin Oncol"},{"key":"2899_CR383","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","volume":"391","author":"MJM van der Valk","year":"2018","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E et al (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study. Lancet 391:2537\u20132545","journal-title":"Lancet"},{"key":"2899_CR384","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/DCR.0000000000002197","volume":"65","author":"GC Cotti","year":"2022","unstructured":"Cotti GC, Pandini RV, Braghiroli OFM et al (2022) Outcomes of patients with local regrowth after nonoperative management of rectal cancer after neoadjuvant chemoradiotherapy. Dis Colon Rectum 65:333\u2013339","journal-title":"Dis Colon Rectum"},{"key":"2899_CR385","doi-asserted-by":"publisher","first-page":"e185896","DOI":"10.1001\/jamaoncol.2018.5896","volume":"5","author":"JJ Smith","year":"2019","unstructured":"Smith JJ, Strombom P, Chow OS et al (2019) Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol 5:e185896","journal-title":"JAMA Oncol"},{"key":"2899_CR386","doi-asserted-by":"publisher","first-page":"e230146","DOI":"10.1001\/jamasurg.2023.0146","volume":"158","author":"PA Custers","year":"2023","unstructured":"Custers PA, van der Sande ME, Grotenhuis BA et al (2023) Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach. JAMA Surg 158:e230146","journal-title":"JAMA Surg"},{"key":"2899_CR387","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/DCR.0000000000000742","volume":"60","author":"K Kawai","year":"2017","unstructured":"Kawai K, Ishihara S, Nozawa H et al (2017) Prediction of pathological complete response using endoscopic findings and outcomes of patients who underwent watchful waiting after chemoradiotherapy for rectal cancer. Dis Colon Rectum 60:368\u2013375","journal-title":"Dis Colon Rectum"},{"key":"2899_CR388","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ejso.2019.10.037","volume":"46","author":"JAW Hagemans","year":"2020","unstructured":"Hagemans JAW, van Rees JM, Alberda WJ et al (2020) Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol 46:448\u2013454","journal-title":"Eur J Surg Oncol"},{"key":"2899_CR389","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/DCR.0000000000000403","volume":"58","author":"G Pellino","year":"2015","unstructured":"Pellino G, Sciaudone G, Candilio G et al (2015) Effect of surgery on health-related quality of life of patients with locally recurrent rectal cancer. Dis Colon Rectum 58:753\u2013761","journal-title":"Dis Colon Rectum"},{"key":"2899_CR390","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/codi.13647","volume":"19","author":"E Rausa","year":"2017","unstructured":"Rausa E, Kelly ME, Bonavina L et al (2017) A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer. Colorectal Dis 19:430\u2013436","journal-title":"Colorectal Dis"},{"key":"2899_CR391","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000070385","volume":"20","author":"N Saito","year":"2003","unstructured":"Saito N, Koda K, Takiguchi N et al (2003) Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg 20:192\u2013199","journal-title":"Dig Surg"},{"key":"2899_CR392","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1245\/s10434-015-4452-0","volume":"22","author":"H Ogawa","year":"2015","unstructured":"Ogawa H, Uemura M, Nishimura J et al (2015) Preoperative chemoradiation followed by extensive pelvic surgery improved the outcome of posterior invasive locally recurrent rectal cancer without deteriorating surgical morbidities: a retrospective, single-institution analysis. Ann Surg Oncol 22:4325\u20134334","journal-title":"Ann Surg Oncol"},{"key":"2899_CR393","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/SLA.0000000000001524","volume":"264","author":"CA Harris","year":"2016","unstructured":"Harris CA, Solomon MJ, Heriot AG et al (2016) The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg 264:323\u2013329","journal-title":"Ann Surg"},{"key":"2899_CR394","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s10350-004-0891-6","volume":"48","author":"M Vermaas","year":"2005","unstructured":"Vermaas M, Ferenschild FT, Nuyttens JJ et al (2005) Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum 48:918\u2013928","journal-title":"Dis Colon Rectum"},{"key":"2899_CR398","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.suronc.2020.08.017","volume":"35","author":"L Sorrentino","year":"2020","unstructured":"Sorrentino L, Belli F, Valvo F et al (2020) Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: impact of anatomical site of pelvic recurrence on long-term results. Surg Oncol 35:89\u201396","journal-title":"Surg Oncol"},{"key":"2899_CR399","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0360-3016(00)01528-5","volume":"49","author":"MG Haddock","year":"2001","unstructured":"Haddock MG, Gunderson LL, Nelson H et al (2001) Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys 49:1267\u20131274","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2899_CR400","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/cncr.10799","volume":"95","author":"M Mohiuddin","year":"2002","unstructured":"Mohiuddin M, Marks G, Marks J (2002) Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 95:1144\u20131150","journal-title":"Cancer"},{"key":"2899_CR401","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/bjs.9569","volume":"101","author":"SJ Bosman","year":"2014","unstructured":"Bosman SJ, Holman FA, Nieuwenhuijzen GAP et al (2014) Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg 101:1280\u20131289","journal-title":"Br J Surg"},{"key":"2899_CR402","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2016.04.022","volume":"96","author":"S Yamada","year":"2016","unstructured":"Yamada S, Kamada T, Ebner DK et al (2016) Carbon-ion radiation therapy for pelvic recurrence of rectal cancer. Int J Radiat Oncol Biol Phys 96:93\u2013101","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2899_CR403","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2018.10.007","volume":"132","author":"M Shinoto","year":"2019","unstructured":"Shinoto M, Yamada S, Okamoto M et al (2019) Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) study 1404 rectum. Radiother Oncol 132:236\u2013240","journal-title":"Radiother Oncol"},{"key":"2899_CR404","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1245\/s10434-021-10876-4","volume":"29","author":"S Yamada","year":"2022","unstructured":"Yamada S, Takiyama H, Isozaki Y et al (2022) Carbon ion radiotherapy for locally recurrent rectal cancer of patients with prior pelvic irradiation. Ann Surg Oncol 29:99\u2013106","journal-title":"Ann Surg Oncol"},{"key":"2899_CR405","doi-asserted-by":"publisher","first-page":"e0162400","DOI":"10.1371\/journal.pone.0162400","volume":"11","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K, Saiura A, Takayama T et al (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400","journal-title":"PLoS ONE"},{"key":"2899_CR406","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","volume":"24","author":"G Portier","year":"2006","unstructured":"Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976\u20134982","journal-title":"J Clin Oncol"},{"key":"2899_CR407","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1200\/JCO.21.01032","volume":"39","author":"Y Kanemitsu","year":"2021","unstructured":"Kanemitsu Y, Shimizu Y, Mizusawa J et al (2021) Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase 2 or 3 randomized controlled trial. J Clin Oncol 39:3789\u20133799","journal-title":"J Clin Oncol"},{"issue":"4","key":"2899_CR408","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.surg.2021.04.012","volume":"170","author":"T Kokudo","year":"2021","unstructured":"Kokudo T, Saiura A, Takayama T et al (2021) Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases. Surgery 170(4):1151\u20131154","journal-title":"Surgery"},{"key":"2899_CR411","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cas.14798","volume":"112","author":"K Akagi","year":"2021","unstructured":"Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112:1105\u20131113","journal-title":"Cancer Sci"},{"key":"2899_CR412","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 21:271\u2013282","journal-title":"Lancet Oncol"},{"key":"2899_CR413","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 21:531\u2013540","journal-title":"Lancet Oncol"},{"key":"2899_CR414","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J et al (2020) Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:1353\u20131365","journal-title":"Lancet Oncol"},{"key":"2899_CR415","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1111\/cas.15826","volume":"114","author":"M Ikegami","year":"2023","unstructured":"Ikegami M (2023) Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain. Cancer Sci 114:3053\u20133055","journal-title":"Cancer Sci"},{"issue":"8","key":"2899_CR416","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s10147-021-01881-4","volume":"26","author":"N Tomita","year":"2021","unstructured":"Tomita N, Ishida H, Tanakaya K et al (2021) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer. Int J Clin Oncol 26(8):1353\u20131419","journal-title":"Int J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02899-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:31Z","timestamp":1764021751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02899-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":409,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2899"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02899-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YK received honoraria from Johnson & Johnson Medtech K.K., Intuitive Surgical G.K., and Medtronic Japan Co., Ltd., received a research funding from Medicaroid Co., Ltd. KU received honoraria from Eli Lilly Japan K.K. YS received honoraria from Olympus Marketing Inc., Erbe Elektromedizin GmbH, Fuji Pharma Co., Ltd., and FUJIFILM Corporation, received research funding from Olympus Corporation. SI received honoraria from Taiho Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd., received a research funding from AbbVie G.K., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Miyarisan Pharmaceutical Co., Ltd., Johnson & Johnson Medtech K.K., and Zeria Pharmaceutical Co., Ltd. TK received honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Taiho Pharmaceutical Co. HK received honoraria from Bristol-Myers Squibb Co., Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd. Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Nippon Kayaku Co. Ltd., GlaxoSmithKline K.K., Amgen Inc., Novartis International AG., and Astellas Pharma Inc., received research funding from Eisai Co., Ltd., Kobayashi Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol Myers Squibb Foundation, and Astellas Pharma Inc. MS received honoraria from Eli Lilly Japan K.K., Takeda Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd., Ono Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co. Ltd. ES received honoraria from Eli Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Merck Biopharma Co., Chugai Pharmaceutical Co., Ltd., TAKATA Pharmaceutical Co., Ltd., Chepra., Daiichi Sankyo Co., Ltd., Guardant Health, Inc. and MSD K.K. AS received honoraria from Johnson & Johnson Medtech K.K., Intuitive Surgical G.K. and Sysmex Corporation. HT received honoraria from Takeda Pharmaceutical Co. Ltd. and Eli Lilly Japan K.K., received research funding from Daiichi Sankyo Co., Ltd. and Ono Pharmaceutical Co. Ltd.. Takako Eguchi Nakajima received research funding from Toregem BioPharma Co., Ltd.\u3001IQVIA Solutions Japan K.K., KBBM, Inc., Takeda Pharmaceutical Co. Thermo Fisher Scientific Inc., Immunohelix Co,. Ltd., Ono Pharmaceutical Co., Ltd. and BTB Therapeutics Inc. KH received research funding from Nippon Chemiphar Co., Ltd. SM received honoraria from AstraZeneca K.K.. Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K. and Ono Pharmaceutical Co. Ltd. KY received honoraria from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Yakult Honsha Co., Ltd., Takeda Pharmaceutical Co. Ltd., Merck & Co., Inc., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., MSD K.K. and Bristol-Myers Squibb Co., Ltd. HK received honoraria from Johnson & Johnson Medtech K.K. and Intuitive Surgical G.K. The other authors declare no conflict of interest. Measures for conflicts of interest: The Guideline Committee and the Guideline Evaluation Committee were organized with members from a diverse range of disciplines, including surgery, internal medicine, radiology, and pathology, to minimize biased opinions. Each recommendation was determined not by individual opinion but through voting by all committee members, with consensus prioritized. When voting on CQ, conflicts related to economic and academic interests were confirmed for each CQ, and members with conflicts of interest abstained from voting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}